(self.webpackChunk_N_E=self.webpackChunk_N_E||[]).push([[9325],{39325:(e,s,r)=>{Promise.resolve().then(r.bind(r,41237))},41237:(e,s,r)=>{"use strict";r.d(s,{default:()=>sM});var a=r(95155),i=r(12115),t=r(76046),n=r(73312),l=r(14505),c=r(87364),o=r(61594),d=r(38002),h=r(85572),m=r(30563),x=r(909),u=r(67732),p=r(22130),j=r(71214),g=r(85608),f=r(21567);let y={light:"",dark:".dark"},v=i.createContext(null);function b(){let e=i.useContext(v);if(!e)throw Error("useChart must be used within a <ChartContainer />");return e}let N=i.forwardRef((e,s)=>{let{id:r,className:t,children:n,config:l,...c}=e,o=i.useId(),d="chart-".concat(r||o.replace(/:/g,""));return(0,a.jsx)(v.Provider,{value:{config:l},children:(0,a.jsxs)("div",{"data-chart":d,ref:s,className:(0,f.cn)("flex aspect-video justify-center text-xs [&_.recharts-cartesian-axis-tick_text]:fill-muted-foreground [&_.recharts-cartesian-grid_line[stroke='#ccc']]:stroke-border/50 [&_.recharts-curve.recharts-tooltip-cursor]:stroke-border [&_.recharts-dot[stroke='#fff']]:stroke-transparent [&_.recharts-layer]:outline-none [&_.recharts-polar-grid_[stroke='#ccc']]:stroke-border [&_.recharts-radial-bar-background-sector]:fill-muted [&_.recharts-rectangle.recharts-tooltip-cursor]:fill-muted [&_.recharts-reference-line_[stroke='#ccc']]:stroke-border [&_.recharts-sector[stroke='#fff']]:stroke-transparent [&_.recharts-sector]:outline-none [&_.recharts-surface]:outline-none",t),...c,children:[(0,a.jsx)(k,{id:d,config:l}),(0,a.jsx)(h.u,{children:n})]})})});N.displayName="Chart";let k=e=>{let{id:s,config:r}=e,i=Object.entries(r).filter(e=>{let[,s]=e;return s.theme||s.color});return i.length?(0,a.jsx)("style",{dangerouslySetInnerHTML:{__html:Object.entries(y).map(e=>{let[r,a]=e;return"\n".concat(a," [data-chart=").concat(s,"] {\n").concat(i.map(e=>{var s;let[a,i]=e,t=(null===(s=i.theme)||void 0===s?void 0:s[r])||i.color;return t?"  --color-".concat(a,": ").concat(t,";"):null}).join("\n"),"\n}\n")}).join("\n")}}):null},A=j.m,C=i.forwardRef((e,s)=>{let{active:r,payload:t,className:n,indicator:l="dot",hideLabel:c=!1,hideIndicator:o=!1,label:d,labelFormatter:h,labelClassName:m,formatter:x,color:u,nameKey:p,labelKey:j}=e,{config:g}=b(),y=i.useMemo(()=>{var e;if(c||!(null==t?void 0:t.length))return null;let[s]=t,r="".concat(j||s.dataKey||s.name||"value"),i=w(g,s,r),n=j||"string"!=typeof d?null==i?void 0:i.label:(null===(e=g[d])||void 0===e?void 0:e.label)||d;return h?(0,a.jsx)("div",{className:(0,f.cn)("font-medium",m),children:h(n,t)}):n?(0,a.jsx)("div",{className:(0,f.cn)("font-medium",m),children:n}):null},[d,h,t,c,m,g,j]);if(!r||!(null==t?void 0:t.length))return null;let v=1===t.length&&"dot"!==l;return(0,a.jsxs)("div",{ref:s,className:(0,f.cn)("grid min-w-[8rem] items-start gap-1.5 rounded-lg border border-border/50 bg-background px-2.5 py-1.5 text-xs shadow-xl",n),children:[v?null:y,(0,a.jsx)("div",{className:"grid gap-1.5",children:t.map((e,s)=>{let r="".concat(p||e.name||e.dataKey||"value"),i=w(g,e,r),t=u||e.payload.fill||e.color;return(0,a.jsx)("div",{className:(0,f.cn)("flex w-full flex-wrap items-stretch gap-2 [&>svg]:h-2.5 [&>svg]:w-2.5 [&>svg]:text-muted-foreground","dot"===l&&"items-center"),children:x&&(null==e?void 0:e.value)!==void 0&&e.name?x(e.value,e.name,e,s,e.payload):(0,a.jsxs)(a.Fragment,{children:[(null==i?void 0:i.icon)?(0,a.jsx)(i.icon,{}):!o&&(0,a.jsx)("div",{className:(0,f.cn)("shrink-0 rounded-[2px] border-[--color-border] bg-[--color-bg]",{"h-2.5 w-2.5":"dot"===l,"w-1":"line"===l,"w-0 border-[1.5px] border-dashed bg-transparent":"dashed"===l,"my-0.5":v&&"dashed"===l}),style:{"--color-bg":t,"--color-border":t}}),(0,a.jsxs)("div",{className:(0,f.cn)("flex flex-1 justify-between leading-none",v?"items-end":"items-center"),children:[(0,a.jsxs)("div",{className:"grid gap-1.5",children:[v?y:null,(0,a.jsx)("span",{className:"text-muted-foreground",children:(null==i?void 0:i.label)||e.name})]}),e.value&&(0,a.jsx)("span",{className:"font-mono font-medium tabular-nums text-foreground",children:e.value.toLocaleString()})]})]})},e.dataKey)})})]})});function w(e,s,r){if("object"!=typeof s||null===s)return;let a="payload"in s&&"object"==typeof s.payload&&null!==s.payload?s.payload:void 0,i=r;return r in s&&"string"==typeof s[r]?i=s[r]:a&&r in a&&"string"==typeof a[r]&&(i=a[r]),i in e?e[i]:e[r]}C.displayName="ChartTooltip",g.s,i.forwardRef((e,s)=>{let{className:r,hideIcon:i=!1,payload:t,verticalAlign:n="bottom",nameKey:l}=e,{config:c}=b();return(null==t?void 0:t.length)?(0,a.jsx)("div",{ref:s,className:(0,f.cn)("flex items-center justify-center gap-4","top"===n?"pb-3":"pt-3",r),children:t.map(e=>{let s="".concat(l||e.dataKey||"value"),r=w(c,e,s);return(0,a.jsxs)("div",{className:(0,f.cn)("flex items-center gap-1.5 [&>svg]:h-3 [&>svg]:w-3 [&>svg]:text-muted-foreground"),children:[(null==r?void 0:r.icon)&&!i?(0,a.jsx)(r.icon,{}):(0,a.jsx)("div",{className:"h-2 w-2 shrink-0 rounded-[2px]",style:{backgroundColor:e.color}}),null==r?void 0:r.label]},e.value)})}):null}).displayName="ChartLegend";var I=r(394),M=r(15255),R=r(12800),S=r(66963),T=r(681),P=r(65512);function B(){let{t:e}=(0,P.B)(),s=[{location:e("progressPage.locations.frontal"),percentage:78.3,key:"frontal"},{location:e("progressPage.locations.temporal"),percentage:45.57,key:"temporal"},{location:e("progressPage.locations.cerebellum"),percentage:37.97,key:"cerebellum"},{location:e("progressPage.locations.basalGanglia"),percentage:27.85,key:"basalGanglia"},{location:e("progressPage.locations.brainStem"),percentage:18.99,key:"brainStem"},{location:e("progressPage.locations.corpusCallosum"),percentage:13,key:"corpusCallosum"}],r={percentage:{label:e("dashboard.stats.overallAccuracy")},frontal:{color:"hsl(var(--chart-1))"},temporal:{color:"hsl(var(--chart-2))"},cerebellum:{color:"hsl(var(--chart-3))"},basalGanglia:{color:"hsl(var(--chart-4))"},brainStem:{color:"hsl(var(--chart-5))"},corpusCallosum:{color:"hsl(var(--chart-1))"}};return(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:e("progressPage.topicBreakdownTitle")}),(0,a.jsx)(p.BT,{children:e("progressPage.topicBreakdownDescription")})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:r,className:"min-h-[250px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:250,children:(0,a.jsxs)(I.E,{data:s,layout:"vertical",margin:{left:10,right:10},children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(R.W,{type:"number",dataKey:"percentage",unit:"%"}),(0,a.jsx)(S.h,{type:"category",dataKey:"location",width:110,tick:{fontSize:12}}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{hideLabel:!0})}),(0,a.jsx)(T.yP,{dataKey:"percentage",radius:5,children:s.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})}let H=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},D=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},L=[{name:"Pure Vasogenic",value:67.09,key:"vasogenic"},{name:"Mixed (Vasogenic + Cytotoxic)",value:32.91,key:"mixed"}],W={vasogenic:{label:"Vasogenic",color:"hsl(var(--chart-1))"},mixed:{label:"Mixed",color:"hsl(var(--chart-2))"}},Z=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},E=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},O=[{name:"DWI Accuracy",sensitivity:93.2,specificity:93.8}],F={sensitivity:{label:"Sensitivity",color:"hsl(var(--chart-1))"},specificity:{label:"Specificity",color:"hsl(var(--chart-2))"}},_=[{name:"rCBV + Ktrans",accuracy:92.8,key:"rcbv"},{name:"18F-FET PET (Recurrence)",accuracy:93,key:"fetRecurrence"},{name:"18F-FET PET (Pseudoprog.)",accuracy:96,key:"fetPseudo"}],G={accuracy:{label:"Diagnostic Accuracy"},rcbv:{color:"hsl(var(--chart-1))"},fetRecurrence:{color:"hsl(var(--chart-2))"},fetPseudo:{color:"hsl(var(--chart-3))"}},z=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},K=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},V=[{name:"MRI (AD vs Healthy)",accuracy:85,type:"sensitivity"},{name:"SPECT (AD vs Healthy)",accuracy:89,type:"sensitivity"},{name:"MRI (Epilepsy Lesions)",accuracy:64,type:"sensitivity"},{name:"CT (Epilepsy Lesions)",accuracy:31,type:"sensitivity"}],q={accuracy:{label:"Sensitivity",color:"hsl(var(--chart-1))"}},J=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},U=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},X=[{name:"DEFUSE 3 Core",value:70,unit:"≤ mL"},{name:"DEFUSE 3 Mismatch Ratio",value:1.8,unit:"≥"},{name:"DAWN Core (NIHSS≥10)",value:30,unit:"< mL"}],Y={value:{label:"Value",color:"hsl(var(--chart-1))"}},Q=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},$=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},ee=[{name:"Ischemic Stroke (IS)",value:65.3,key:"ischemic"},{name:"Intracerebral Hemorrhage (ICH)",value:28.8,key:"ich"},{name:"Subarachnoid Hemorrhage (SAH)",value:5.8,key:"sah"}],es={ischemic:{label:"Ischemic Stroke (IS)",color:"hsl(var(--chart-1))"},ich:{label:"Intracerebral Hemorrhage (ICH)",color:"hsl(var(--chart-2))"},sah:{label:"Subarachnoid Hemorrhage (SAH)",color:"hsl(var(--chart-3))"}},er=[{name:"High BP",value:56.8,key:"risk1"},{name:"High BMI",value:37,key:"risk2"},{name:"Air Pollution",value:16.6,key:"risk3"},{name:"Smoking",value:13.7,key:"risk4"},{name:"High Glucose",value:17.1,key:"risk5"}],ea={risk1:{label:"High BP",color:"hsl(var(--chart-1))"},risk2:{label:"High BMI",color:"hsl(var(--chart-2))"},risk3:{label:"Air Pollution",color:"hsl(var(--chart-3))"},risk4:{label:"Smoking",color:"hsl(var(--chart-4))"},risk5:{label:"High Glucose",color:"hsl(var(--chart-5))"}},ei=[{name:"Undetermined",value:26,key:"subtype1"},{name:"Large Artery",value:23,key:"subtype2"},{name:"Cardioembolism",value:22,key:"subtype3"},{name:"Small Vessel",value:22,key:"subtype4"}],et={subtype1:{label:"Undetermined",color:"hsl(var(--muted-foreground))"},subtype2:{label:"Large Artery",color:"hsl(var(--chart-1))"},subtype3:{label:"Cardioembolism",color:"hsl(var(--chart-2))"},subtype4:{label:"Small Vessel",color:"hsl(var(--chart-4))"}},en=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},el=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},ec=[{name:"Lobar Cerebral Microbleeds",prevalence:92.5,key:"lobar"},{name:"WMHs (Multispot)",prevalence:50,key:"wmh"},{name:"Enlarged PVS",prevalence:50,key:"pvs"},{name:"Cortical Superficial Siderosis",prevalence:47.8,key:"siderosis"},{name:"Cerebellar Microbleeds",prevalence:38.8,key:"cerebellar"}],eo={prevalence:{label:"Prevalence (%)"},lobar:{color:"hsl(var(--chart-1))"},wmh:{color:"hsl(var(--chart-2))"},pvs:{color:"hsl(var(--chart-3))"},siderosis:{color:"hsl(var(--chart-4))"},cerebellar:{color:"hsl(var(--chart-5))"}},ed=[{version:"v1.5",sensitivity:70.8,specificity:88.8},{version:"v2.0",sensitivity:79.8,specificity:84.7}],eh={sensitivity:{label:"Sensitivity",color:"hsl(var(--chart-1))"},specificity:{label:"Specificity",color:"hsl(var(--chart-2))"}},em=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},ex=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},eu=[{name:"Anti-NMDAR",association:40,key:"antiNmdar"},{name:"Anti-GABABR",association:60,key:"antiGababr"},{name:"Anti-AMPAR",association:60,key:"antiAmpar"},{name:"Anti-Hu (ANNA-1)",association:90,key:"antiHu"},{name:"Anti-Ma2 (Ta)",association:90,key:"antiMa2"}],ep={association:{label:"Malignancy Association (%)"},antiNmdar:{label:"Anti-NMDAR",color:"hsl(var(--chart-1))"},antiGababr:{label:"Anti-GABABR",color:"hsl(var(--chart-2))"},antiAmpar:{label:"Anti-AMPAR",color:"hsl(var(--chart-3))"},antiHu:{label:"Anti-Hu",color:"hsl(var(--chart-4))"},antiMa2:{label:"Anti-Ma2",color:"hsl(var(--chart-5))"}},ej=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},eg=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},ef=[{name:"Hormonal Therapy",value:23.4,key:"risk1"},{name:"Pregnancy/Puerperium",value:20,key:"risk2"},{name:"Infections",value:15,key:"risk3"},{name:"Thrombophilias",value:10,key:"risk4"},{name:"Other/Unknown",value:31.6,key:"risk5"}],ey={risk1:{label:"Hormonal Therapy",color:"hsl(var(--chart-1))"},risk2:{label:"Pregnancy/Puerperium",color:"hsl(var(--chart-2))"},risk3:{label:"Infections",color:"hsl(var(--chart-3))"},risk4:{label:"Thrombophilias",color:"hsl(var(--chart-4))"},risk5:{label:"Other/Unknown",color:"hsl(var(--chart-5))"}},ev=[{stage:"At Diagnosis",mRS_0_1:18.7},{stage:"At 3 Months",mRS_0_1:83.2},{stage:"At 6 Months",mRS_0_1:85.1}],eb={mRS_0_1:{label:"Good Outcome (mRS 0-1)",color:"hsl(var(--chart-1))"}},eN=[{name:"General Population",rate:5,key:"mortality1"},{name:"Obstetric Cases",rate:18.5,key:"mortality2"},{name:"Vaccine-Induced",rate:50,key:"mortality3"},{name:"Endovascular Tx",rate:9.2,key:"mortality4"}],ek={rate:{label:"Mortality Rate (%)"},mortality1:{color:"hsl(var(--chart-1))"},mortality2:{color:"hsl(var(--chart-2))"},mortality3:{color:"hsl(var(--chart-3))"},mortality4:{color:"hsl(var(--chart-4))"}},eA=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},eC=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},ew=[{name:"Endovascular Therapy (PTAS + AMM)",value:14.7,key:"ptas"},{name:"Medical Management (AMM)",value:5.8,key:"amm"}],eI={ptas:{label:"PTAS Arm",color:"hsl(var(--chart-2))"},amm:{label:"Medical Arm",color:"hsl(var(--chart-1))"}},eM=[{name:"Ischemic Stroke (10.2%)",value:23,key:"ischemic"},{name:"Hemorrhagic Stroke (4.5%)",value:10,key:"hemorrhagic"}],eR={ischemic:{label:"Ischemic Stroke",color:"hsl(var(--chart-1))"},hemorrhagic:{label:"Hemorrhagic Stroke",color:"hsl(var(--chart-2))"}},eS=[{name:"Perforator Strokes (52%)",value:12,key:"perforator"},{name:"Other Ischemic Infarcts (48%)",value:11,key:"other"}],eT={perforator:{label:"Perforator Strokes",color:"hsl(var(--chart-4))"},other:{label:"Other Ischemic",color:"hsl(var(--chart-5))"}},eP=[{name:"Diameter < 0.6 mm",value:10,key:"smallDiameter"},{name:"Diameter > 0.6 mm",value:0,key:"largeDiameter"}],eB={smallDiameter:{label:"<0.6mm",color:"hsl(var(--chart-2))"},largeDiameter:{label:">0.6mm",color:"hsl(var(--chart-1))"}},eH=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},eD=e=>{let{path:s,className:r="text-primary"}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 mr-3 flex-shrink-0 ".concat(r),xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},eL=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},eW=e=>{let{path:s,className:r="text-primary"}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 mr-3 flex-shrink-0 ".concat(r),xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},eZ=[{name:"Incidental Lesions",risk:.08,key:"risk1"},{name:"Non-Brainstem (No Prior ICH)",risk:.3,key:"risk2"},{name:"Brainstem (No Prior ICH)",risk:2.8,key:"risk3"},{name:"Non-Brainstem (Post-ICH)",risk:6.3,key:"risk4"},{name:"Brainstem (Post-ICH)",risk:32.3,key:"risk5"}],eE={risk:{label:"Annual Risk"},risk1:{color:"hsl(var(--chart-1))"},risk2:{color:"hsl(var(--chart-2))"},risk3:{color:"hsl(var(--chart-3))"},risk4:{color:"hsl(var(--chart-4))"},risk5:{color:"hsl(var(--chart-5))"}},eO=[{name:"Brainstem w/ ICH",risk:30.8},{name:"Other w/ ICH",risk:18.4},{name:"Brainstem w/o ICH",risk:8},{name:"Other w/o ICH",risk:3.8}],eF={risk:{label:"5-Year ICH Risk (%)",color:"hsl(var(--chart-3))"}},e_=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},eG=e=>{let{path:s,className:r="text-primary"}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 mr-3 flex-shrink-0 ".concat(r),xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},ez=[{name:"Hypertensive Arteriopathy",value:55,key:"etio1"},{name:"Coagulopathy / Antithrombotic Use",value:20,key:"etio2"},{name:"Cerebral Amyloid Angiopathy (CAA)",value:15,key:"etio3"},{name:"Vascular Malformations",value:5,key:"etio4"},{name:"Brain Tumors",value:5,key:"etio5"}],eK={value:{label:"Prevalence"},etio1:{label:"Hypertensive Arteriopathy",color:"hsl(var(--chart-1))"},etio2:{label:"Coagulopathy",color:"hsl(var(--chart-2))"},etio3:{label:"CAA",color:"hsl(var(--chart-3))"},etio4:{label:"Vascular Malformations",color:"hsl(var(--chart-4))"},etio5:{label:"Brain Tumors",color:"hsl(var(--chart-5))"}},eV=[{name:"Ruptured Aneurysm",value:85,key:"aneurysm"},{name:"Non-Aneurysmal Causes",value:15,key:"nonAneurysm"}],eq={value:{label:"Prevalence"},aneurysm:{label:"Ruptured Aneurysm",color:"hsl(var(--chart-2))"},nonAneurysm:{label:"Non-Aneurysmal",color:"hsl(var(--muted-foreground))"}},eJ=[{name:"Aneurysm Prevalence (General Pop.)",rate:4,key:"prev"},{name:"Annual Rupture Risk (Unruptured)",rate:6,key:"rupture"},{name:"Re-bleeding Risk (2 Weeks Post-Rupture)",rate:20,key:"rebleed"}],eU={rate:{label:"Rate (%)"},prev:{color:"hsl(var(--chart-1))"},rupture:{color:"hsl(var(--chart-3))"},rebleed:{color:"hsl(var(--chart-2))"}},eX=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},eY=e=>{let{path:s,className:r="text-primary"}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 mr-3 flex-shrink-0 ".concat(r),xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},eQ=[{name:"Chronic Alcohol Users",value:13,key:"riskHigh"},{name:"General Population",value:1.5,key:"riskLow"}],e$={riskHigh:{label:"Chronic Alcohol Users",color:"hsl(var(--chart-5))"},riskLow:{label:"General Population",color:"hsl(var(--chart-1))"}},e0=[{name:"Classic Triad Present",value:24.5,key:"classic"},{name:"Atypical/Subclinical",value:75.5,key:"atypical"}],e1={classic:{label:"Classic Triad",color:"hsl(var(--chart-2))"},atypical:{label:"Atypical/Subclinical",color:"hsl(var(--muted))"}},e2=[{name:"Sensitivity",value:53,key:"sensitivity"},{name:"Specificity",value:93,key:"specificity"}],e5={sensitivity:{label:"Sensitivity",color:"hsl(var(--chart-1))"},specificity:{label:"Specificity",color:"hsl(var(--chart-2))"}},e3=[{name:"Medial Thalamus / 3rd Ventricle",frequency:82.5,key:"loc1"},{name:"Periaqueductal Area",frequency:62,key:"loc2"},{name:"Mammillary Bodies",frequency:41.5,key:"loc3"},{name:"Midbrain Tectum",frequency:37,key:"loc4"}],e7={loc1:{label:"Medial Thalamus",color:"hsl(var(--chart-1))"},loc2:{label:"Periaqueductal",color:"hsl(var(--chart-2))"},loc3:{label:"Mammillary Bodies",color:"hsl(var(--chart-3))"},loc4:{label:"Midbrain Tectum",color:"hsl(var(--chart-4))"}},e6=[{name:"Genu",reduction:18,key:"genu"},{name:"Truncus",reduction:16,key:"truncus"},{name:"Splenium",reduction:15,key:"splenium"}],e4={genu:{label:"Genu",color:"hsl(var(--chart-3))"},truncus:{label:"Truncus",color:"hsl(var(--chart-4))"},splenium:{label:"Splenium",color:"hsl(var(--chart-5))"}},e8=[{name:"Associated with AUD",value:50.5,key:"aud"},{name:"Other Causes",value:49.5,key:"other"}],e9={aud:{label:"AUD-Associated",color:"hsl(var(--chart-5))"},other:{label:"Other Causes",color:"hsl(var(--muted))"}};var se=r(72508);let ss=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},sr=e=>{let{path:s}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 text-primary mr-3 flex-shrink-0",xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},sa=[{name:"Fourth Ventricle",frequency:56.5,key:"loc1"},{name:"Lateral Ventricles",frequency:25,key:"loc2"},{name:"Third Ventricle",frequency:10,key:"loc3"},{name:"Aqueduct",frequency:8.5,key:"loc4"}],si={loc1:{label:"Fourth Ventricle",color:"hsl(var(--chart-1))"},loc2:{label:"Lateral Ventricles",color:"hsl(var(--chart-2))"},loc3:{label:"Third Ventricle",color:"hsl(var(--chart-3))"},loc4:{label:"Aqueduct",color:"hsl(var(--chart-4))"}},st=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},sn=e=>{let{path:s,className:r="text-primary"}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 mr-3 flex-shrink-0 ".concat(r),xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},sl=[{grade:"WHO Grade 2",survival:95,key:"grade2"},{grade:"WHO Grade 3",survival:75,key:"grade3"}],sc={survival:{label:"5-Year Survival"},grade2:{color:"hsl(var(--chart-2))"},grade3:{color:"hsl(var(--chart-5))"}},so=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-secondary text-transparent bg-clip-text",children:s})},sd=e=>{let{path:s,className:r="text-primary"}=e;return(0,a.jsx)("svg",{className:"h-8 w-8 mr-3 flex-shrink-0 ".concat(r),xmlns:"http://www.w3.org/2000/svg",fill:"none",viewBox:"0 0 24 24",strokeWidth:"1.5",stroke:"currentColor",children:(0,a.jsx)("path",{strokeLinecap:"round",strokeLinejoin:"round",d:s})})},sh=[{grade:"WHO Grade 2",survival:78,key:"grade2"},{grade:"WHO Grade 3",survival:30,key:"grade3"}],sm={survival:{label:"5-Year Survival"},grade2:{color:"hsl(var(--chart-1))"},grade3:{color:"hsl(var(--chart-5))"}},sx=[{name:"Pineoblastoma",ageGroup:"Pediatric (<20 yrs)",key:"pineoblastoma"},{name:"Germinoma",ageGroup:"Pediatric/Young Adult",key:"germinoma"},{name:"Pineocytoma",ageGroup:"Adult (20-60 yrs)",key:"pineocytoma"},{name:"PPTID",ageGroup:"Adult (20-70 yrs)",key:"pptid"}],su={pineoblastoma:{color:"hsl(var(--chart-5))"},germinoma:{color:"hsl(var(--chart-4))"},pineocytoma:{color:"hsl(var(--chart-1))"},pptid:{color:"hsl(var(--chart-2))"}};var sp=r(48617),sj=r(51072),sg=r(3897),sf=r(23494),sy=r(23888),sv=r(4068);let sb=e=>{let{children:s}=e;return(0,a.jsx)("span",{className:"bg-gradient-to-r from-primary to-blue-600 dark:to-blue-400 text-transparent bg-clip-text",children:s})},sN=e=>{let{icon:s,className:r="text-primary"}=e;return(0,a.jsx)(s,{className:"h-8 w-8 mr-3 flex-shrink-0 ".concat(r)})},sk=[{group:"General Population",rate:.46,key:"gp"},{group:"HIV+ (Post-HAART)",rate:1,key:"immuno"},{group:"Elderly (65+)",rate:2,key:"elderly"}],sA={rate:{label:"Rate per 100k/year"},gp:{label:"General Population",color:"hsl(var(--chart-1))"},immuno:{label:"HIV+ (Post-HAART)",color:"hsl(var(--chart-3))"},elderly:{label:"Elderly (65+)",color:"hsl(var(--chart-2))"}},sC=[{group:"Immunocompetent",survival:30.1,key:"immunoComp"},{group:"HIV+",survival:9,key:"hiv"}],sw={survival:{label:"5-Year Survival (%)"},immunoComp:{label:"Immunocompetent",color:"hsl(var(--chart-2))"},hiv:{label:"HIV+",color:"hsl(var(--chart-5))"}},sI={pres_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Posterior Reversible Encephalopathy Syndrome ",(0,a.jsx)(H,{children:"(PRES)"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"A Guide to Clinicoradiological Findings"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(D,{path:"M9.813 15.904L9 18.75l-.813-2.846a4.5 4.5 0 00-3.09-3.09L2.25 12l2.846-.813a4.5 4.5 0 003.09-3.09L9 5.25l.813 2.846a4.5 4.5 0 003.09 3.09L15.75 12l-2.846.813a4.5 4.5 0 00-3.09 3.09zM18.259 8.715L18 9.75l-.259-1.035a3.375 3.375 0 00-2.455-2.456L14.25 6l1.036-.259a3.375 3.375 0 002.455-2.456L18 2.25l.259 1.035a3.375 3.375 0 002.456 2.456L21.75 6l-1.035.259a3.375 3.375 0 00-2.456 2.456zM16.898 20.648l.21-1.05a2.25 2.25 0 00-1.58-2.618l-1.05-.21a2.25 2.25 0 00-2.618 1.58l-.21 1.05a2.25 2.25 0 001.58 2.618l1.05.21a2.25 2.25 0 002.618-1.58z"}),"I. General MRI Characteristics & Edema Type"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Vasogenic Edema (Typical)"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"High ADC values"}),(0,a.jsx)("li",{children:"Iso- or hypointense on DWI"}),(0,a.jsx)("li",{children:"May show T2 shine-through effect on DWI"})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Cytotoxic Edema (Less Common)"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"Bright signal on DWI"}),(0,a.jsx)("li",{children:"Decreased ADC values"}),(0,a.jsx)("li",{children:"Correlates with larger vasogenic edema areas"})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Edema Composition (Study of 79 Patients)"}),(0,a.jsx)(p.BT,{children:"Percentage distribution of edema types."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:W,className:"min-h-[200px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(m.r,{children:[(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{hideLabel:!0})}),(0,a.jsx)(x.Fq,{data:L,dataKey:"value",nameKey:"name",cx:"50%",cy:"50%",outerRadius:80,label:!0,children:L.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(D,{path:"M11.25 11.25l.041-.02a.75.75 0 011.063.852l-.708 2.836a.75.75 0 001.063.853l.041-.021M21 12a9 9 0 11-18 0 9 9 0 0118 0zm-9-3.75h.008v.008H12V8.25z"}),"II. Etiologies & Risk Factors"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary mb-2",children:"Most Frequent Associations"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground space-y-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("span",{className:"font-semibold text-foreground",children:"Hypertension:"})," Present in 84-100% of patients at onset."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("span",{className:"font-semibold text-foreground",children:"(Pre)eclampsia:"})," A significant risk factor, found in 44.3% of patients in one study."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("span",{className:"font-semibold text-foreground",children:"Renal Disease/Failure:"})," Common cause, including chronic renal failure (31.6% in one study) and glomerulonephritis."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("span",{className:"font-semibold text-foreground",children:"Autoimmune Disorders:"})," Systemic lupus erythematosus (SLE) found in 38% of patients in one study."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("span",{className:"font-semibold text-foreground",children:"Cytotoxic/Immunosuppressive Meds:"})," Used in chemotherapy and post-transplant."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("span",{className:"font-semibold text-foreground",children:"Sepsis:"})," Especially when associated with acute kidney injury."]})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary mb-2",children:"Demographics & Other Causes"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground space-y-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("span",{className:"font-semibold text-foreground",children:"Gender:"})," Higher occurrence in females (ratio up to 1:5.57)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("span",{className:"font-semibold text-foreground",children:"Age:"})," Can occur in any age group; mean age in pediatrics is ~10-11 years."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("span",{className:"font-semibold text-foreground",children:"Other Causes:"})," Organ transplantation, sickle cell anemia, vasculitis, certain toxins, and metabolic disturbances like hypomagnesaemia."]})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(D,{path:"M12 9.75v6.75m0 0l-3-3m3 3l3-3m-8.25 6a4.5 4.5 0 01-1.41-8.775 5.25 5.25 0 0110.233-2.33 3 3 0 013.758 3.848A3.752 3.752 0 0118 19.5H6.75z"}),"III. Lesion Location & Distribution"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Typical Pattern: Posterior Dominance"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"Predominantly affects subcortical white matter of posterior lobes. Usually symmetrical and bilateral."}),(0,a.jsxs)("div",{className:"flex flex-wrap gap-6 mt-2",children:[(0,a.jsxs)("div",{className:"text-center",children:[(0,a.jsx)("p",{className:"text-3xl font-bold text-foreground",children:"~100%"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"Parietal Lobe"})]}),(0,a.jsxs)("div",{className:"text-center",children:[(0,a.jsx)("p",{className:"text-3xl font-bold text-foreground",children:"~85%"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"Occipital Lobe"})]})]})]}),(0,a.jsx)(B,{})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(D,{path:"M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z"}),"IV. Atypical Imaging Features"]})}),(0,a.jsxs)(p.Wu,{className:"space-y-5",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Contrast Enhancement"}),(0,a.jsxs)("p",{className:"text-base mt-1 text-muted-foreground",children:["Seen in ",(0,a.jsx)("span",{className:"text-foreground font-bold",children:"21-50%"})," of patients. Does not correlate with functional outcome."]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Hemorrhage"}),(0,a.jsxs)("p",{className:"text-base mt-1 text-muted-foreground",children:["Occurs in ",(0,a.jsx)("span",{className:"text-foreground font-bold",children:"5-30%"})," of cases and doesn't exclude PRES. Can be intraparenchymal, microbleeds, or subarachnoid."]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Restricted Diffusion"}),(0,a.jsxs)("p",{className:"text-base mt-1 text-muted-foreground",children:["Indicates cytotoxic edema. Found in ",(0,a.jsx)("span",{className:"text-foreground font-bold",children:"17-33%"})," of cases. Can lead to permanent injury."]})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(D,{path:"M19.5 12c0-1.232-.046-2.453-.138-3.662a4.006 4.006 0 00-3.7-3.7 48.678 48.678 0 00-7.324 0 4.006 4.006 0 00-3.7 3.7c-.092 1.21-.138 2.43-.138 3.662v1.562a4.006 4.006 0 003.7 3.7c1.846.053 3.695.085 5.568 0a4.006 4.006 0 003.7-3.7v-1.562zM12 15.75a3 3 0 01-3-3h6a3 3 0 01-3 3z"}),"V. Resolution & Prognosis"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsxs)("p",{className:"text-muted-foreground mb-4 text-base",children:["While PRES is typically ",(0,a.jsx)("span",{className:"text-primary font-semibold",children:"reversible"}),", it's not always complete. Follow-up imaging is crucial."]}),(0,a.jsxs)("div",{className:"bg-muted p-4 rounded-lg",children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Resolution Timeline"}),(0,a.jsxs)("p",{className:"text-base text-muted-foreground",children:["Median time for MRI lesion improvement/disappearance: ",(0,a.jsx)("span",{className:"text-foreground font-bold",children:"9 days"})," (range 3-60 days)."]}),(0,a.jsxs)("p",{className:"text-base text-muted-foreground mt-1",children:[(0,a.jsx)("span",{className:"text-foreground font-bold",children:"~40%"})," may have residual structural lesions on follow-up."]})]}),(0,a.jsxs)("div",{className:"mt-4 bg-destructive/10 border border-destructive/20 p-4 rounded-lg",children:[(0,a.jsx)("h3",{className:"font-semibold text-destructive",children:"Features Associated with Poor Outcomes"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-destructive/90 mt-2 space-y-1",children:[(0,a.jsx)("li",{children:"Extensive or worsening edema"}),(0,a.jsx)("li",{children:"Intracranial / Subarachnoid hemorrhage"}),(0,a.jsx)("li",{children:"Restrictive diffusion (cytotoxic edema)"}),(0,a.jsx)("li",{children:"Corpus callosum involvement"})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(D,{path:"M21 21l-5.197-5.197m0 0A7.5 7.5 0 105.196 5.196a7.5 7.5 0 0010.607 10.607z"}),"VI. Diagnostic Considerations"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"MRI vs. CT"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"MRI is more sensitive/specific. CT is often the first test and may show hypodense areas (92.3% in one pediatric study)."}),(0,a.jsx)("h3",{className:"font-semibold text-foreground mt-4",children:"Differential Diagnosis"}),(0,a.jsxs)("p",{className:"text-base text-muted-foreground",children:[(0,a.jsx)("span",{className:"font-bold text-primary",children:"Acute Ischemic Stroke:"})," Typically shows cytotoxic edema (restricted diffusion) in a unilateral vascular territory."]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Role of Digital Subtraction Angiography (DSA)"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"Not routine, but considered for suspected RCVS or other arteriopathies. Can reveal:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground/90 mt-1 pl-2 space-y-1",children:[(0,a.jsx)("li",{children:"Diffuse vasoconstriction & vessel pruning."}),(0,a.jsx)("li",{children:"Up to 87% of PRES cases show angiographic changes consistent with RCVS."}),(0,a.jsx)("li",{children:"MRI remains the primary diagnostic tool."})]})]})]})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key clinicoradiological findings of PRES based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"http://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on July 3, 2025. Generated with Gemini."]})]})]}),brain_lesion_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Differentiating Brain ",(0,a.jsx)(Z,{children:"Lesions"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"Tumors vs. Non-Neoplastic Conditions"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(E,{path:"M21 21l-5.197-5.197m0 0A7.5 7.5 0 105.196 5.196a7.5 7.5 0 0010.607 10.607z"}),"Why is Accurate Diagnosis Crucial?"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"Observing multiple lesions on a skull CT or MRI is a cause for concern, often pointing to a neoplastic etiology. However, a wide range of non-neoplastic conditions can mimic brain tumors, creating a potential pitfall. Accurate differentiation is critical because treatment strategies differ completely: ischemic lesions are treated with anticoagulants, demyelinating lesions with steroids, infections with targeted agents, and tumors often require surgery or radiotherapy. Due to potential neuroradiological misdiagnosis, histological analysis (biopsy) is frequently necessary for a definitive diagnosis."})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(E,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 11-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"1. Brain Abscesses (Infectious)"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsxs)("p",{className:"text-base text-muted-foreground",children:["An intracerebral abscess is an encapsulated collection of pus, accounting for ~2% of intracranial mass lesions. Bacteria are responsible for ",">","95% of cases in immunocompetent patients."]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Imaging Characteristics:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**Conventional MRI:** Typically a ring-enhancing lesion with a smooth, complete capsule. Often surrounded by vasogenic edema."}),(0,a.jsx)("li",{children:"**DWI/ADC:** Hallmark feature is **restricted diffusion** within the central core (hyperintense on DWI, hypointense on ADC)."}),(0,a.jsx)("li",{children:"**MRS:** Shows raised choline, reduced NAA, and prominent lipid and lactate peaks."})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"DWI Diagnostic Accuracy"}),(0,a.jsx)(p.BT,{children:"For differentiating abscesses from other lesions."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:F,className:"min-h-[150px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:O,children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"name",tickLine:!1,tickMargin:10,axisLine:!1}),(0,a.jsx)(S.h,{unit:"%"}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"sensitivity",fill:"var(--color-sensitivity)",radius:[4,4,0,0]}),(0,a.jsx)(T.yP,{dataKey:"specificity",fill:"var(--color-specificity)",radius:[4,4,0,0]})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(E,{path:"M12 9.75v6.75m0 0l-3-3m3 3l3-3m-8.25 6a4.5 4.5 0 01-1.41-8.775 5.25 5.25 0 0110.233-2.33 3 3 0 013.758 3.848A3.752 3.752 0 0118 19.5H6.75z"}),"2. Brain Tumors (Neoplastic)"]})}),(0,a.jsxs)(p.Wu,{className:"space-y-4",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Imaging Characteristics:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**Conventional MRI:** Can also be ring-enhancing, but often with irregular or incomplete rims."}),(0,a.jsx)("li",{children:"**DWI/ADC:** Necrotic tumors typically have **elevated ADC values** (no restricted diffusion), unlike abscesses."}),(0,a.jsx)("li",{children:"**MRS:** Characterized by raised choline, reduced NAA, and increased Cho/NAA and Cho/Cr ratios."}),(0,a.jsx)("li",{children:"**Perfusion MRI:** Tumor recurrence shows significantly **higher rCBV** and Ktrans values."}),(0,a.jsx)("li",{children:"**Amino Acid PET:** Shows **higher uptake** in tumor tissue compared to treatment-related changes."})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Advanced Imaging Accuracy"}),(0,a.jsx)(p.BT,{children:"For differentiating tumor recurrence from necrosis."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:G,className:"min-h-[200px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:_,layout:"vertical",children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(S.h,{dataKey:"name",type:"category",tickLine:!1,tickMargin:10,axisLine:!1,width:180,tick:{fontSize:14}}),(0,a.jsx)(R.W,{dataKey:"accuracy",type:"number",unit:"%"}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"accuracy",radius:[0,4,4,0],barSize:30,children:_.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(E,{path:"M3.75 12h16.5m-16.5 3.75h16.5M3.75 19.5h16.5M5.625 4.5h12.75a1.875 1.875 0 010 3.75H5.625a1.875 1.875 0 010-3.75z"}),"3. Radiation Necrosis (Non-Neoplastic)"]})}),(0,a.jsxs)(p.Wu,{className:"space-y-4",children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"A severe local tissue reaction after radiotherapy, typically 3-12 months post-treatment. It involves vascular injury, glial damage, and inflammation."}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Imaging Characteristics:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**Conventional MRI:** Mimics tumor recurrence with increased, often irregular, contrast enhancement."}),(0,a.jsx)("li",{children:"**MRS:** Characterized by **lower Cho/Cr and Cho/NAA ratios** compared to recurrent tumors."}),(0,a.jsx)("li",{children:"**Perfusion MRI:** Shows **lower rCBV and Ktrans values** compared to tumor recurrence."}),(0,a.jsx)("li",{children:"**Amino Acid PET:** Typically shows **lower uptake** compared to active tumor tissue."})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(E,{path:"M3.75 6.75h16.5M3.75 12h16.5m-16.5 5.25h16.5"}),"Other Mimics & Diagnostic Summary"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Other Non-Neoplastic Mimics:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**Infarcts:** Can sometimes mimic high-grade gliomas."}),(0,a.jsx)("li",{children:"**Inflammatory/Granulomatous Lesions:** Tuberculomas, fungal infections."}),(0,a.jsx)("li",{children:'**Demyelinating Diseases:** Tumefactive MS, PML (often with "open ring" enhancement).'}),(0,a.jsx)("li",{children:"**Vascular Diseases:** Such as vasculitis."})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Summary of Diagnostic Approach:"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"A multi-modal imaging approach is necessary. While conventional MRI provides anatomy, advanced techniques like DWI, MRS, and Perfusion MRI offer crucial functional and metabolic information. PET/CT further enhances accuracy. In challenging cases, **histopathological analysis remains the gold standard**."})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(E,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-sm text-muted-foreground columns-1 md:columns-2",children:[(0,a.jsx)("li",{className:"break-inside-avoid",children:"1. Babar, M., et al. (2015). *Pak J Med Health Sci*. (No DOI provided)"}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["2. Chuang, M.-T., et al. (2016). *PLoS One*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1371/journal.pone.0141438",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1371/journal.pone.0141438"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["3. Feraco, P., et al. (2020). *J Pract Transl Clin Pharmacol*. ",(0,a.jsx)("a",{href:"https://doi.org/10.15586/jptcp.v27i3.688",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.15586/jptcp.v27i3.688"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["4. Feng, A., et al. (2022). *Acad Radiol*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/j.acra.2021.11.008",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/j.acra.2021.11.008"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["5. Grabovetskyi, S. (2015). *J Cancer Prev Curr Res*. ",(0,a.jsx)("a",{href:"https://doi.org/10.15406/jcpcr.2015.02.00052",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.15406/jcpcr.2015.02.00052"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["6. Lasocki, A., et al. (2025). *J Med Imaging Radiat Oncol*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1111/1754-9485.13847",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1111/1754-9485.13847"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["7. Rabelo, N. N., et al. (2016). *Arq Bras Neurocir*. ",(0,a.jsx)("a",{href:"http://dx.doi.org/10.1055/s-0035-1570362",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1055/s-0035-1570362"})]}),(0,a.jsx)("li",{className:"break-inside-avoid",children:"8. Raiyani, J. J., et al. (2024). *Int J Med Health Res*. (No DOI provided)"}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["9. Usuda, K., et al. (2021). *Cancers*. ",(0,a.jsx)("a",{href:"https://doi.org/10.3390/cancers13112720",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.3390/cancers13112720"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["10. Zikou, A., et al. (2018). *BioMed Res Int*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1155/2018/6828396",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1155/2018/6828396"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key clinicoradiological findings of Differentiating Brain Lesions based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on July 3, 2025. Generated with Gemini."]})]})]}),neuroimaging_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Neuroimaging Modalities and ",(0,a.jsx)(z,{children:"Intracerebral Hemorrhage"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"A Guide to Key Diagnostic Applications"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(K,{path:"M3.75 6.75h16.5M3.75 12h16.5m-16.5 5.25h16.5"}),"Overview of Neuroimaging"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"Neuroimaging is fundamental for diagnosing and managing a wide range of brain conditions, from acute events like stroke and hemorrhage to chronic diseases such as Alzheimer's and epilepsy. Advanced imaging modalities like Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), including specialized sequences, provide critical insights into brain pathology, guiding immediate treatment and long-term patient care."})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(K,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"Intracerebral Hemorrhage (ICH)"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"Accounts for 10-20% of annual strokes in the US, with a 40% mortality rate within one month. Non-contrast CT (NCCT) is the first-line modality for acute diagnosis."}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"MRI's Pivotal Role:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"Nearly 100% sensitivity and specificity for diagnosing ICH."}),(0,a.jsx)("li",{children:"Crucial for detailed assessment and determining hemorrhage age."}),(0,a.jsx)("li",{children:"**SWI/GRE:** Highly sensitive for microbleeds."}),(0,a.jsx)("li",{children:"**DWI:** Remote lesions increase risk of subsequent ischemic stroke 2.5x."}),(0,a.jsx)("li",{children:"**FLAIR:** Used to quantify perihematomal edema (PHE)."})]})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Hemorrhage Staging by MRI Signal:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsxs)("li",{children:["**Hyperacute (","<","24h):** T1 iso, T2 hyperintense, DWI high, ADC low."]}),(0,a.jsx)("li",{children:"**Acute (1-3d):** T1 iso, T2 low, DWI low, ADC low."}),(0,a.jsx)("li",{children:"**Early Subacute (3-7d):** T1 high, T2 low."}),(0,a.jsx)("li",{children:"**Late Subacute (7-28d):** T1 high, T2 high."}),(0,a.jsxs)("li",{children:["**Chronic (",">","1mo):** T1 low, T2 high (center) with low signal rim."]})]})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(K,{path:"M12 9.75v6.75m0 0l-3-3m3 3l3-3m-8.25 6a4.5 4.5 0 01-1.41-8.775 5.25 5.25 0 0110.233-2.33 3 3 0 013.758 3.848A3.752 3.752 0 0118 19.5H6.75z"}),"SAH & Diffuse Axonal Injury (DAI)"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Subarachnoid Hemorrhage (SAH)"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**NCCT:** Standard for acute diagnosis, but can have false negatives."}),(0,a.jsx)("li",{children:"**MRI (FLAIR & T2*):** More useful than CT for detecting SAH, with sensitivity up to 94-100% depending on timing."})]}),(0,a.jsxs)("div",{className:"mt-4",children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Diffuse Axonal Injury (DAI)"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**MRI:** Recommended and more sensitive than CT for detecting small hemorrhagic foci."}),(0,a.jsx)("li",{children:"**SWI:** Significantly outperforms T2* for DAI detection; lesion count correlates with prognosis."})]})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(K,{path:"M3.75 12h16.5m-16.5 3.75h16.5M3.75 19.5h16.5M5.625 4.5h12.75a1.875 1.875 0 010 3.75H5.625a1.875 1.875 0 010-3.75z"}),"Acute Cerebral Infarction & Reperfusion"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground mb-4",children:"Imaging is essential for determining indication for reperfusion therapy while minimizing delay."}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**NCCT:** Recommended to exclude hemorrhage and evaluate early ischemic changes (ASPECTS)."}),(0,a.jsx)("li",{children:"**MRI (DWI):** Highly sensitive for early changes. DWI-ASPECTS is a superior predictor of outcomes compared to CT-ASPECTS."}),(0,a.jsx)("li",{children:"**Perfusion Imaging (CT/MR):** Useful for evaluating perfusion-core mismatch in patients 6-24 hours after onset."}),(0,a.jsx)("li",{children:"**CTA/MRA:** Necessary if endovascular therapy is considered, but should not delay IV rt-PA."})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(K,{path:"M9.813 15.904L9 18.75l-.813-2.846a4.5 4.5 0 00-3.09-3.09L2.25 12l2.846-.813a4.5 4.5 0 003.09-3.09L9 5.25l.813 2.846a4.5 4.5 0 003.09 3.09L15.75 12l-2.846.813a4.5 4.5 0 00-3.09 3.09z"}),"Chronic Diseases & Space-Occupying Lesions"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Temporal Lobe Epilepsy"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"MRI is the first-choice modality. CT sensitivity is much lower (31% vs. 64% for MRI)."})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Alzheimer's Disease (AD)"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"MRI detects medial temporal lobe atrophy. SPECT and PET assess blood flow and metabolism."})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Metastatic Brain Tumors"}),(0,a.jsxs)("p",{className:"text-base text-muted-foreground mt-1",children:["Contrast-enhanced MRI is superior to CT. 3T MRI improves detection of small lesions (","<","5mm)."]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Primary Headache"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Imaging is not routinely recommended unless headache is atypical (e.g., thunderclap)."})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Diagnostic Sensitivity"}),(0,a.jsx)(p.BT,{children:"In selected chronic conditions."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:q,className:"min-h-[200px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:V,layout:"vertical",children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(S.h,{dataKey:"name",type:"category",tickLine:!1,tickMargin:10,axisLine:!1,width:150,tick:{fontSize:14}}),(0,a.jsx)(R.W,{dataKey:"accuracy",type:"number",unit:"%"}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"accuracy",fill:"var(--color-accuracy)",radius:[0,4,4,0],barSize:30})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(K,{path:"M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z"}),"Amyloid-Related Imaging Abnormalities (ARIA)"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Overview:"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Imaging findings associated with amyloid-modifying therapies, classified as ARIA-E (edema/effusions) and ARIA-H (hemorrhages)."}),(0,a.jsx)("h3",{className:"font-semibold text-foreground mt-4",children:"Prevalence & Risk Factors:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"ARIA-E occurred in 9.7% to 35.2% of patients in clinical trials."}),(0,a.jsx)("li",{children:"Risk factors include higher drug doses and APOE4 carrier status."})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Imaging Features:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**ARIA-E (Edema):** Best visualized on FLAIR MRI. Typically shows an absence of diffusion restriction."}),(0,a.jsx)("li",{children:"**ARIA-H (Hemorrhage):** Microhemorrhages are best detected with T2*-GRE and SWI sequences."})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(K,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-sm text-muted-foreground columns-1 md:columns-2",children:[(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Babi, M. A., et al. (2025). *Frontiers in Neuroscience*. ",(0,a.jsx)("a",{href:"https://doi.org/10.3389/fnins.2025.1593225",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.3389/fnins.2025.1593225"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Heit, J. J., et al. (2017). *Journal of Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.5853/jos.2016.00563",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.5853/jos.2016.00563"})]}),(0,a.jsx)("li",{className:"break-inside-avoid",children:"American Heart Association. (2025). *Circulation Research*. (No DOI provided)"}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Linfante, I., et al. (1999). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/01.STR.30.11.2263",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/01.STR.30.11.2263"})]}),(0,a.jsx)("li",{className:"break-inside-avoid",children:"[Anonymous]. (n.d.). *1 Neuroradiology (Excerpts)*. (No DOI provided)"}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Penckofer, M., et al. (2024). *Frontiers in Neuroscience*. ",(0,a.jsx)("a",{href:"https://doi.org/10.3389/fnins.2024.1408288",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.3389/fnins.2024.1408288"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Shen, Y., et al. (2022). *Magnetic Resonance Imaging*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/j.mri.2022.08.009",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/j.mri.2022.08.009"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Vukmir, R. B. (2024). *Annals of Clinical and Translational Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1002/acn3.52042",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1002/acn3.52042"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Weerink, L. B. M., et al. (2023). *British Journal of Radiology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1259/bjr.20220304",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1259/bjr.20220304"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key findings on Neuroimaging Modalities and Intracerebral Hemorrhage based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"http://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on July 3, 2025. Generated with Gemini."]})]})]}),acute_ischemic_stroke_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Acute Ischemic Stroke: ",(0,a.jsx)(J,{children:"Perfusion Imaging"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"A Guide to CTP, MRP, and Clinical Applications"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(U,{path:"M3.75 6.75h16.5M3.75 12h16.5m-16.5 5.25h16.5"}),"Introduction"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"Acute ischemic stroke is a leading cause of morbidity and mortality. Rapid and accurate diagnosis using advanced imaging like CT Perfusion (CTP) and MR Perfusion (MRP) is crucial for identifying salvageable brain tissue (penumbra) and guiding reperfusion therapies."})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(U,{path:"M9.813 15.904L9 18.75l-.813-2.846a4.5 4.5 0 00-3.09-3.09L2.25 12l2.846-.813a4.5 4.5 0 003.09-3.09L9 5.25l.813 2.846a4.5 4.5 0 003.09 3.09L15.75 12l-2.846.813a4.5 4.5 0 00-3.09 3.09z"}),"1. Understanding Acute Ischemic Stroke: Infarction & Penumbra"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-destructive",children:"Ischemic Core (Infarction)"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Brain tissue with irreversible damage due to severe ischemia. On imaging, it shows severely reduced Cerebral Blood Flow (CBF) and Cerebral Blood Volume (CBV). It is generally not salvageable."})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-green-600 dark:text-green-400",children:"Ischemic Penumbra"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Critically hypoperfused but still viable tissue surrounding the core. It is the primary target for reperfusion therapies. On imaging, it has reduced CBF but relatively preserved CBV."})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(U,{path:"M12 9.75v6.75m0 0l-3-3m3 3l3-3m-8.25 6a4.5 4.5 0 01-1.41-8.775 5.25 5.25 0 0110.233-2.33 3 3 0 013.758 3.848A3.752 3.752 0 0118 19.5H6.75z"}),"2. Imaging Techniques to Assess Perfusion"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsx)("h3",{className:"font-semibold text-primary text-lg",children:"CT Perfusion (CTP)"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"Involves acquiring multiple brain scans over time after an IV contrast injection. It results in a higher radiation dose than multiphase CTA."}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h4",{className:"font-semibold text-secondary",children:"Key CTP Parameters:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"CBV (Cerebral Blood Volume):"})," Total blood volume in a brain region. A decrease suggests infarcted tissue (core)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"CBF (Cerebral Blood Flow):"})," Blood volume flow per minute. A relative CBF of ","<","30% of normal is a validated marker for the ischemic core."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"MTT (Mean Transit Time):"})," Average time for contrast to pass through capillaries. Prolonged MTT can be protective."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Tmax (Time to Maximum):"})," Contrast bolus delay. Tmax ",">="," 6 seconds is considered to define the ischemic penumbra."]})]})]})]}),(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsx)("h3",{className:"font-semibold text-primary text-lg",children:"MR Perfusion (MRP)"}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h4",{className:"font-semibold text-secondary",children:"Dynamic Susceptibility Contrast (DSC-MRI):"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Measures T2* signal drop during contrast passage. Does not provide reliable absolute quantification of CBF and CBV."})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h4",{className:"font-semibold text-secondary",children:"Arterial Spin Labeling (ASL):"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Provides quantitative information without exogenous contrast. Allows for repeated measurements but has a lower signal-to-noise ratio."})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h4",{className:"font-semibold text-secondary",children:"DWI-PWI Mismatch:"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"The mismatch between the DWI lesion (core) and the larger perfusion defect on PWI approximates the penumbra. A large mismatch suggests a favorable response to reperfusion."})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h4",{className:"font-semibold text-secondary",children:"DWI-FLAIR Mismatch:"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"For wake-up strokes, a visible DWI lesion without a corresponding FLAIR signal suggests the stroke occurred within a treatable window (approx. 4.5 hours)."})]})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(U,{path:"M3.75 12h16.5m-16.5 3.75h16.5M3.75 19.5h16.5M5.625 4.5h12.75a1.875 1.875 0 010 3.75H5.625a1.875 1.875 0 010-3.75z"}),"3. Defining Infarct & Penumbra"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Mismatch Concept:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Ischemic Core:"})," Defined by critically low CBF (","<","30% of normal) on CTP or the DWI lesion on MRP."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Penumbra:"})," Defined by prolonged transit times (Tmax ",">"," 6s) but relatively preserved CBV."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Mismatch:"})," The goal is to find a small core and a large penumbra (Mismatch = Total Hypoperfused Volume - Core Volume)."]})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(U,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 11-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"Key Thresholds & Landmark Trials"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground mb-4",children:'Recent clinical trials like DAWN and DEFUSE 3 have established the benefit of mechanical thrombectomy in extended time windows (up to 24 hours) for patients selected based on perfusion mismatch criteria. These trials have shifted stroke care from a "time-based" to a "tissue-based" approach.'}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Patient Selection Criteria (DAWN & DEFUSE 3)"}),(0,a.jsx)(p.BT,{children:"Key volumetric and ratio thresholds for thrombectomy."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:Y,className:"min-h-[200px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:X,children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"name",tickLine:!1,tickMargin:10,axisLine:!1}),(0,a.jsx)(S.h,{}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"value",fill:"var(--color-value)",radius:[4,4,0,0],barSize:40})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(U,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-sm text-muted-foreground columns-1 md:columns-2",children:[(0,a.jsxs)("li",{className:"break-inside-avoid",children:["1. Astrup, J., et al. (1981). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/01.str.12.6.723",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/01.str.12.6.723"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["2. Campbell, B. C., et al. (2012). *J Cereb Blood Flow Metab*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1038/jcbfm.2011.102",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1038/jcbfm.2011.102"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["3. Olivot, J. M., et al. (2014). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STROKEAHA.113.003857",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STROKEAHA.113.003857"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["4. d’Esterre, C. D., et al. (2015). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STROKEAHA.115.009250",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STROKEAHA.115.009250"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["5. Campbell, B. C. V., et al. (2019). *Lancet Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/s1474-4422(18)30314-4",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/s1474-4422(18)30314-4"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["6. Demeestere, J., et al. (2020). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STROKEAHA.119.032924",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STROKEAHA.119.032924"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["7. Saver, J. L., et al. (2020). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STROKEAHA.120.030332",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STROKEAHA.120.030332"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["8. Turc, G., et al. (2023). *J NeuroInterventional Surg*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1136/neurintsurg-2018-014569",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1136/neurintsurg-2018-014569"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["9. Bivard, A., et al. (2013). *Radiology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1148/radiol.12120971",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1148/radiol.12120971"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["10. Powers, W. J., et al. (2019). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STR.0000000000000211",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STR.0000000000000211"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key concepts in Perfusion Imaging for Acute Ischemic Stroke based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on July 3, 2025. Generated with Gemini."]})]})]}),stroke_subtypes_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Ischemic vs. Hemorrhagic ",(0,a.jsx)(Q,{children:"Stroke"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"A Comparative Analysis of Demographics, Statistics, and Epidemiology"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)($,{path:"M3.75 6.75h16.5M3.75 12h16.5m-16.5 5.25h16.5"}),"Ischemic vs. Hemorrhagic Stroke: An Overview"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Ischemic Stroke (IS)"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Occurs when a blood vessel supplying the brain is blocked by a clot, leading to insufficient blood flow. It accounts for the vast majority of strokes."})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-destructive",children:"Hemorrhagic Stroke (HS)"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Occurs when a blood vessel in the brain ruptures, causing bleeding into the brain (ICH) or the surrounding space (SAH)."})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)($,{path:"M9.813 15.904L9 18.75l-.813-2.846a4.5 4.5 0 00-3.09-3.09L2.25 12l2.846-.813a4.5 4.5 0 003.09-3.09L9 5.25l.813 2.846a4.5 4.5 0 003.09 3.09L15.75 12l-2.846.813a4.5 4.5 0 00-3.09 3.09z"}),"1. Incidence and Prevalence by Subtype"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"The proportion of stroke subtypes varies globally, with high-income countries (HICs) having a higher proportion of ischemic strokes compared to low- and middle-income countries (LMICs)."}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Geographical Variation:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**HICs:** ~74.9% of incident strokes are ischemic."}),(0,a.jsx)("li",{children:"**LMICs:** Higher relative proportion of hemorrhagic strokes."})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Global Stroke Prevalence (2021)"}),(0,a.jsx)(p.BT,{children:"Approximate percentage of all incident strokes."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:es,className:"min-h-[200px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(m.r,{children:[(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{hideLabel:!0})}),(0,a.jsx)(x.Fq,{data:ee,dataKey:"value",nameKey:"name",cx:"50%",cy:"50%",outerRadius:80,label:!0,children:ee.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)($,{path:"M12 9.75v6.75m0 0l-3-3m3 3l3-3m-8.25 6a4.5 4.5 0 01-1.41-8.775 5.25 5.25 0 0110.233-2.33 3 3 0 013.758 3.848A3.752 3.752 0 0118 19.5H6.75z"}),"2. Epidemiology: Key Modifiable Risk Factors"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground lg:col-span-2",children:"Up to 90% of all stroke cases globally could be preventable by addressing modifiable risk factors. High systolic blood pressure is the single most important factor."}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Contribution to Stroke DALYs (2021)"}),(0,a.jsx)(p.BT,{children:"Percentage of Disability-Adjusted Life Years."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:ea,className:"min-h-[250px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:250,children:(0,a.jsxs)(I.E,{data:er,layout:"vertical",margin:{left:10,right:10},children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(R.W,{type:"number",dataKey:"value",unit:"%"}),(0,a.jsx)(S.h,{type:"category",dataKey:"name",width:80,tick:{fontSize:12}}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"value",radius:[0,4,4,0],barSize:30,children:er.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Etiological Subtypes of Ischemic Stroke"}),(0,a.jsx)(p.BT,{children:"Approximate distribution percentage."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:et,className:"min-h-[250px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:250,children:(0,a.jsxs)(m.r,{children:[(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{hideLabel:!0})}),(0,a.jsx)(x.Fq,{data:ei,dataKey:"value",nameKey:"name",cx:"50%",cy:"50%",outerRadius:80,label:!0,children:ei.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)($,{path:"M3.75 12h16.5m-16.5 3.75h16.5M3.75 19.5h16.5M5.625 4.5h12.75a1.875 1.875 0 010 3.75H5.625a1.875 1.875 0 010-3.75z"}),"3. Specific Risk Factors by Stroke Subtype"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Ischemic Stroke Specific Risk Factors"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**Atrial Fibrillation (AF):** Powerful risk factor for cardioembolic stroke."}),(0,a.jsx)("li",{children:"**Atherosclerosis:** Drives large vessel ischemic stroke."}),(0,a.jsx)("li",{children:"**Diabetes Mellitus:** Strongly associated with small vessel (lacunar) stroke."}),(0,a.jsx)("li",{children:"**Dyslipidemia:** High LDL cholesterol linked to atherosclerotic stroke."})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-destructive",children:"Hemorrhagic Stroke Specific Risk Factors"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**Uncontrolled Hypertension:** The dominant risk factor for ICH (up to 65% of cases)."}),(0,a.jsx)("li",{children:"**Anticoagulation Therapy:** Significantly increases ICH risk."}),(0,a.jsx)("li",{children:"**Cerebral Amyloid Angiopathy (CAA):** A leading cause of lobar ICH in older adults."}),(0,a.jsx)("li",{children:"**Smoking & Alcohol:** Strongly linked to SAH and ICH."})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)($,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 11-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"4. Diagnostic Imaging Considerations"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Computed Tomography (CT)"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Initial modality of choice due to speed and high sensitivity for acute hemorrhage."}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-2 space-y-1",children:[(0,a.jsx)("li",{children:"**Hemorrhagic Stroke:** Appears as a **hyperdense (bright white)** area immediately."}),(0,a.jsx)("li",{children:"**Ischemic Stroke:** May be normal initially, becoming **hypodense (darker)** within 24-48 hours."})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Magnetic Resonance Imaging (MRI)"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Provides more detail and detects acute ischemic changes earlier than CT."}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-2 space-y-1",children:[(0,a.jsx)("li",{children:"**Ischemic Stroke:** **DWI** is the most sensitive sequence, showing a bright signal within minutes."}),(0,a.jsx)("li",{children:"**Hemorrhagic Stroke:** Appearance is complex and varies with age. **SWI/GRE** sequences are highly sensitive for blood products, which appear very dark."})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)($,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-sm text-muted-foreground columns-1 md:columns-2",children:[(0,a.jsxs)("li",{className:"break-inside-avoid",children:["GBD 2021 Stroke Collaborators. (2024). *The Lancet Neurology*. ",(0,a.jsx)("a",{href:"https://www.healthdata.org/research-analysis/library/global-regional-and-national-burden-stroke-and-its-risk-factors-1990-2021",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"healthdata.org"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Feigin, V. L., et al. (2020). *The Lancet Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/S1474-4422(20)30500-0",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/S1474-4422(20)30500-0"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Tsao, C. W., et al. (2025). *Circulation*. ",(0,a.jsx)("a",{href:"https://www.heart.org/en/-/media/PHD-Files-2/Science-News/2/2025-Heart-and-Stroke-Stat-Update/2025-Statistics-At-A-Glance.pdf",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"heart.org"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Yang, Z., et al. (2025). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STROKEAHA.122.040073",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STROKEAHA.122.040073"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Sun, J., et al. (2024). *Journal of the American Heart Association*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/JAHA.124.039387",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/JAHA.124.039387"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Kleindorfer, D. O., et al. (2021). *The Lancet Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/S1474-4422(21)00022-6",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/S1474-4422(21)00022-6"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Diringer, M. N., & Hemphill, J. C., III. (2023). *StatPearls*. ",(0,a.jsx)("a",{href:"https://www.ncbi.nlm.nih.gov/books/NBK559173/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"ncbi.nlm.nih.gov"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Fonseca, A. C., & Ferro, J. M. (2015). *J Neurol Sci*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/j.jns.2014.07.039",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/j.jns.2014.07.039"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Spiotta, A. M., et al. (2024). *Br J Radiol*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1259/bjr.20230571",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1259/bjr.20230571"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Li, M., et al. (2024). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STROKEAHA.123.045154",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STROKEAHA.123.045154"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key distinctions between Ischemic and Hemorrhagic Stroke based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on July 3, 2025. Generated with Gemini."]})]})]}),cerebral_amyloid_angiopathy_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Cerebral Amyloid ",(0,a.jsx)(en,{children:"Angiopathy (CAA)"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"A Summary of Pathophysiology, Imaging, and Clinical Concepts"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(el,{path:"M9.813 15.904L9 18.75l-.813-2.846a4.5 4.5 0 00-3.09-3.09L2.25 12l2.846-.813a4.5 4.5 0 003.09-3.09L9 5.25l.813 2.846a4.5 4.5 0 003.09 3.09L15.75 12l-2.846.813a4.5 4.5 0 00-3.09 3.09z"}),"1. Pathophysiology and Core Concepts"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"CAA is a small vessel disease characterized by amyloid-beta (Aβ) protein deposition in the walls of small to medium-sized arteries, arterioles, and capillaries in the cerebral cortex and leptomeninges. This accumulation leads to vessel fragility, increasing the risk of hemorrhage. Dysfunctional perivascular spaces (PVSs) may contribute by limiting Aβ clearance."})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(el,{path:"M15.042 21.002a2.25 2.25 0 01-3.084 0 2.25 2.25 0 01-3.084 0M12 6.002v9.75m-3.111 2.553a.75.75 0 01-1.06 0l-3-3a.75.75 0 011.06-1.06l1.06 1.06 4.765-4.764a.75.75 0 111.06 1.06l-5.25 5.25-1.591 1.591z"}),"2. Clinical Manifestations"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Cognitive Impairment (57.4%):"})," Especially in executive function and processing speed."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Intracerebral Hemorrhage (42.6%):"})," A primary manifestation, particularly lobar hemorrhages."]}),(0,a.jsx)("li",{children:(0,a.jsx)("strong",{children:"Behavioral/Psychiatric Signs (27.9%)"})}),(0,a.jsx)("li",{children:(0,a.jsx)("strong",{children:"Headache (25.0%)"})}),(0,a.jsx)("li",{children:(0,a.jsx)("strong",{children:"Transient Focal Neurological Episodes (20.6%)"})}),(0,a.jsx)("li",{children:(0,a.jsx)("strong",{children:"Seizures (16.2%)"})})]})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(el,{path:"M2.25 15.75l5.159-5.159a2.25 2.25 0 013.182 0l5.159 5.159m-1.5-1.5l1.409-1.409a2.25 2.25 0 013.182 0l2.909 2.909m-18 3.75h16.5a1.5 1.5 0 001.5-1.5V6a1.5 1.5 0 00-1.5-1.5H3.75A1.5 1.5 0 002.25 6v12a1.5 1.5 0 001.5 1.5zm10.5-11.25h.008v.008h-.008V8.25zm.375 0a.375.375 0 11-.75 0 .375.375 0 01.75 0z"}),"3. Key Imaging Markers & Prevalence"]}),(0,a.jsx)(p.BT,{children:"Data from a prospective cohort study."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:eo,className:"min-h-[250px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:250,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:ec,layout:"vertical",margin:{left:150,right:20},children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(S.h,{dataKey:"name",type:"category",tickLine:!1,tickMargin:10,axisLine:!1,width:150,tick:{fontSize:10}}),(0,a.jsx)(R.W,{dataKey:"prevalence",type:"number",unit:"%"}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"prevalence",name:"Prevalence",radius:[0,4,4,0],barSize:25,children:ec.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(el,{path:"M3.75 12h16.5m-16.5 3.75h16.5M3.75 19.5h16.5M5.625 4.5h12.75a1.875 1.875 0 010 3.75H5.625a1.875 1.875 0 010-3.75z"}),"4. Boston Criteria v2.0 for Probable CAA"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:'The Boston Criteria v2.0 classify CAA based on clinical and imaging findings, with "Probable CAA" being the highest certainty in living patients without biopsy.'}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Core Requirements:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsxs)("li",{children:["Age ",">="," 50 years with spontaneous Intracerebral Hemorrhage, Transient Focal Neurological Episodes, or cognitive impairment."]}),(0,a.jsx)("li",{children:"Absence of deep hemorrhagic lesions (Intracerebral Hemorrhage or Cerebral Microbleeds)."}),(0,a.jsx)("li",{children:"Absence of other causes for hemorrhage."})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Required MRI Patterns (Either A or B):"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"A:"})," ",">=","2 strictly lobar hemorrhagic lesions (Intracerebral Hemorrhage, Cerebral Microbleeds, Cortical Superficial Siderosis)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"B:"})," 1 lobar hemorrhagic lesion + 1 white matter feature (severe PVS or multispot WMH)."]})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Boston Criteria v2.0 vs v1.5 Accuracy"}),(0,a.jsx)(p.BT,{children:"For probable CAA diagnosis (vs. non-probable)."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:eh,className:"min-h-[150px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:ed,children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"version",tickLine:!1,tickMargin:10,axisLine:!1}),(0,a.jsx)(S.h,{unit:"%"}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(g.s,{}),(0,a.jsx)(T.yP,{dataKey:"sensitivity",fill:"var(--color-sensitivity)",radius:[4,4,0,0],name:"Sensitivity"}),(0,a.jsx)(T.yP,{dataKey:"specificity",fill:"var(--color-specificity)",radius:[4,4,0,0],name:"Specificity"})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(el,{path:"M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z"}),"5. Risk Factors & Clinical Implications"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Hypertension:"})," Present in 70.6% of CAA patients in one study. Visit-to-visit BP variability is linked to Cerebral Microbleed and WMH progression."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Anticoagulation Decisions:"})," A diagnosis of CAA is a strong contraindication for antithrombotic therapy due to the high risk of recurrent Intracerebral Hemorrhage."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Risk Stratification:"})," The Boston Criteria help stratify the risk of recurrent Intracerebral Hemorrhage. v2.0 may identify a wider spectrum of the disease."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Cognitive Impairment:"})," CAA is a significant contributor to age-related cognitive decline, and early diagnosis can inform prognosis and management."]})]})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(el,{path:"M16.023 9.348h4.992v-.001a.75.75 0 01.75.75c0 .414-.336.75-.75.75h-4.992a2.25 2.25 0 01-2.25-2.25V6.75A2.25 2.25 0 0112 4.5v-2.25c0-.414.336-.75.75-.75s.75.336.75.75V4.5a.75.75 0 00.75.75h3.037a.75.75 0 010 1.5H13.5a.75.75 0 00-.75.75V9a2.25 2.25 0 012.273-2.25zM5.25 6.75c0-.414.336-.75.75-.75H9a.75.75 0 010 1.5H6a.75.75 0 000 1.5h3a.75.75 0 010 1.5H6a.75.75 0 000 1.5h3a.75.75 0 010 1.5H6a.75.75 0 00-.75.75v1.5c0 .414-.336.75-.75.75s-.75-.336-.75-.75v-1.5A2.25 2.25 0 015.25 9V6.75z"}),"6. Risk of Recurrent Hemorrhage"]})}),(0,a.jsxs)(p.Wu,{className:"space-y-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Annual Risk of a New Bleed"}),(0,a.jsxs)("p",{className:"text-center text-3xl font-bold text-destructive my-2",children:["7% - 14% ",(0,a.jsx)("span",{className:"text-lg text-muted-foreground font-medium",children:"per year"})]}),(0,a.jsx)("p",{className:"text-xs text-center text-muted-foreground",children:"For a survivor of a CAA-related lobar hemorrhage. This risk depends on MRI factors."})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Timeline of Risk"}),(0,a.jsxs)("div",{className:"grid grid-cols-1 sm:grid-cols-2 gap-4 mt-2",children:[(0,a.jsxs)(p.Zp,{className:"bg-destructive/10 border-destructive/20",children:[(0,a.jsx)(p.aR,{className:"p-3",children:(0,a.jsx)(p.ZB,{className:"text-base text-destructive",children:"Early Recurrence (First 90 Days)"})}),(0,a.jsx)(p.Wu,{className:"p-3 pt-0",children:(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-1",children:"The risk is maximal in the first 3 months, often reflecting a more severe disease burden on MRI."})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{className:"p-3",children:(0,a.jsx)(p.ZB,{className:"text-base text-foreground",children:"Chronic Risk (After 90 Days)"})}),(0,a.jsx)(p.Wu,{className:"p-3 pt-0",children:(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-1",children:"After the initial period, the risk stabilizes to a sustained annual rate due to the progressive nature of CAA."})})]})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Key MRI Predictors of Future Bleeds"}),(0,a.jsxs)("ul",{className:"space-y-2 mt-2 text-sm text-muted-foreground",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Cortical Superficial Siderosis (cSS):"})," The single strongest predictor. Widespread cSS elevates the annual risk to nearly 19%."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Cerebral Microbleeds (CMBs):"})," A high number of strictly lobar CMBs is associated with an annual recurrence risk of over 10%."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Genetic Factors (APOE Alleles):"})," APOE ε2 is strongly associated with a higher risk of recurrent hemorrhage, while ε4 is linked to a higher overall amyloid burden."]})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(el,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"7. Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-sm text-muted-foreground columns-1 md:columns-2",children:[(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Charidimou, A., et al. (2022). *Lancet Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/S1474-4422(22)00208-3",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/S1474-4422(22)00208-3"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Chen, S.-J., & Tsai, H.-H. (2019). *Ther Adv Neurol Disord*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1177/1756286419844113",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1177/1756286419844113"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Greenberg, S. M., & Charidimou, A. (2018). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STROKEAHA.117.016990",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STROKEAHA.117.016990"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Kozberg, M. G. (2020). *Int J Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1177/1747493020974464",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1177/1747493020974464"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Panteleienko, L., et al. (2024). *Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1212/WNL.0000000000210084",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1212/WNL.0000000000210084"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Samarasekera, N., et al. (2017). *PLoS ONE*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1371/journal.pone.0180923",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1371/journal.pone.0180923"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Schrag, M., & Kirshner, H. (2016). *Curr Neurol Neurosci Rep*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1007/s11910-016-0674-1",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1007/s11910-016-0674-1"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Storti, B., et al. (2023). *Frontiers in Neuroscience*. ",(0,a.jsx)("a",{href:"https://doi.org/10.3389/fnins.2023.1219025",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.3389/fnins.2023.1219025"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Tanaka, F., et al. (2024). *Jpn J Radiol*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1007/s11604-024-01720-2",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1007/s11604-024-01720-2"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Theodorou, A., et al. (2023). *J Clin Med*. ",(0,a.jsx)("a",{href:"https://doi.org/10.3390/jcm12175591",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.3390/jcm12175591"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key findings on Cerebral Amyloid Angiopathy (CAA) based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on October 3, 2025. Generated with Gemini."]})]})]}),limbic_encephalitis_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Diagnostic Criteria for ",(0,a.jsx)(em,{children:"Limbic Encephalitis"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"A Guide to Clinical, Imaging, and Laboratory Findings"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(ex,{path:"M9 12.75L11.25 15 15 9.75M21 12a9 9 0 11-18 0 9 9 0 0118 0z"}),"Diagnostic Criteria for Probable Autoimmune Encephalitis"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("p",{className:"text-muted-foreground mb-4",children:"Based on Graus et al. (2016), all three of the following criteria must be met for a diagnosis of probable AE:"}),(0,a.jsxs)("div",{className:"grid grid-cols-1 lg:grid-cols-3 gap-4",children:[(0,a.jsxs)("div",{className:"p-4 bg-muted/50 rounded-lg",children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"1. Subacute Onset"}),(0,a.jsxs)("p",{className:"text-sm text-muted-foreground mt-1",children:["Rapid progression (","<","3 months) of working memory deficits, altered mental status, or psychiatric symptoms."]})]}),(0,a.jsxs)("div",{className:"p-4 bg-muted/50 rounded-lg",children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"2. At Least One Supportive Feature"}),(0,a.jsx)("p",{className:"text-sm text-muted-foreground mt-1",children:"New focal CNS findings, new-onset seizures, supportive MRI, or CSF pleocytosis."})]}),(0,a.jsxs)("div",{className:"p-4 bg-muted/50 rounded-lg",children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"3. Reasonable Exclusion"}),(0,a.jsx)("p",{className:"text-sm text-muted-foreground mt-1",children:"Alternative causes must be reasonably ruled out."})]})]}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-4",children:"A definitive diagnosis requires the identification of a specific neural autoantibody."})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(ex,{path:"M9.813 15.904L9 18.75l-.813-2.846a4.5 4.5 0 00-3.09-3.09L2.25 12l2.846-.813a4.5 4.5 0 003.09-3.09L9 5.25l.813 2.846a4.5 4.5 0 003.09 3.09L15.75 12l-2.846.813a4.5 4.5 0 00-3.09 3.09z"}),"Neuroimaging: MRI Features in Limbic Encephalitis"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"MRI is the modality of choice, but a normal MRI does not exclude the diagnosis. Findings are observed in ~60-90% of patients, but MRI can be normal in up to 50% of anti-NMDAR encephalitis cases. Subtle or transient lesions can also lead to false negatives."}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Typical Findings (T2/FLAIR):"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**Medial Temporal Lobe (MTL) Hyperintensity:** The hallmark finding, often unilateral or bilateral, involving the hippocampus and amygdala."}),(0,a.jsx)("li",{children:"**Absence of Mass Effect:** Typically no significant mass effect."}),(0,a.jsx)("li",{children:"**Contrast Enhancement:** Uncommon, but can be seen as patchy or linear enhancement."}),(0,a.jsx)("li",{children:"**DWI:** Usually normal or shows non-restrictive diffusion, distinguishing it from stroke."}),(0,a.jsx)("li",{children:"**Atrophy:** Hippocampal atrophy can be seen in chronic or recurrent cases."})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Recommended MRI Protocol"}),(0,a.jsx)(p.BT,{children:"For optimal visualization of limbic structures."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-2",children:[(0,a.jsx)("li",{children:"T1-weighted (pre and post-contrast)"}),(0,a.jsx)("li",{children:"T2-weighted and FLAIR sequences"}),(0,a.jsx)("li",{children:"Diffusion-Weighted Imaging (DWI) & ADC maps"}),(0,a.jsx)("li",{children:"Susceptibility-Weighted Imaging (SWI/GRE)"}),(0,a.jsx)("li",{children:"Thin-section coronal imaging of the hippocampus"})]})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(ex,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 11-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"CSF Biomarkers & Antibody Testing"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Key CSF Findings"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsxs)("li",{children:["**Pleocytosis:** Elevated WBC (",">","5 cells/mm\xb3), found in 50-80% of patients."]}),(0,a.jsx)("li",{children:"**Elevated Protein:** Increased protein concentration is frequently seen."}),(0,a.jsx)("li",{children:"**Oligoclonal Bands (OCBs):** Can be present, indicating intrathecal inflammation."}),(0,a.jsx)("li",{children:"**Normal Glucose:** Helps differentiate from bacterial meningitis."}),(0,a.jsx)("li",{children:"**Exclusion of Infections:** PCR for viruses like HSV is crucial."})]}),(0,a.jsx)("h3",{className:"font-semibold text-primary mt-4",children:"Antibodies to Cell-Surface Proteins"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Often more responsive to immunotherapy. Includes Anti-NMDAR, LGI1, CASPR2, GABABR, AMPAR, DPPX, and IgLON5."}),(0,a.jsx)("h3",{className:"font-semibold text-primary mt-4",children:"Antibodies to Intracellular Proteins"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Anti-Hu (ANNA-1):"})," Strong association with SCLC (",">","90%). Presents with multifocal deficits."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Anti-Ma2 (Ta):"})," Associated with testicular germ cell tumors (",">","90%) and SCLC."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Anti-CV2/CRMP5:"})," Associated with SCLC and thymoma (",">","90%)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Anti-Amphiphysin:"})," Associated with SCLC and breast cancer (",">","90%)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Anti-GAD65:"})," Tumor association is variable (~25%)."]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Malignancy Association of Key Antibodies"}),(0,a.jsx)(p.BT,{children:"Approximate percentage of cases associated with tumors."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:ep,className:"min-h-[250px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:250,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:eu,layout:"vertical",children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(S.h,{dataKey:"name",type:"category",tickLine:!1,tickMargin:10,axisLine:!1,width:100}),(0,a.jsx)(R.W,{dataKey:"association",type:"number",unit:"%"}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"association",radius:[0,4,4,0],barSize:30,children:eu.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(ex,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-sm text-muted-foreground columns-1 md:columns-2",children:[(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Graus, F., et al. (2025). *J Neurol Neurosurg Psychiatry*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1136/jnnp-2024-330514",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1136/jnnp-2024-330514"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Graus, F., et al. (2016). *Lancet Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/S1474-4422(15)00401-9",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/S1474-4422(15)00401-9"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Bien, C. G., & Bien, B. A. (2025). *Curr Treat Options Neurol*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1007/s11940-025-00858-6",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1007/s11940-025-00858-6"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Kelley, B. P., & Mammen, A. L. (2019). *Curr Med Sci*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1007/s11596-019-2092-7",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1007/s11596-019-2092-7"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Patel, H., & Irani, S. R. (2024). *Neurol Clin Pract*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1212/CPJ.0000000000200000",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1212/CPJ.0000000000200000"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Dubey, D., & Toledano, M. (2025). *NeuroImage: Clinical*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/j.nicl.2025.103987",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/j.nicl.2025.103987"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Hoang-Phoung, P., & Dalmau, J. (2022). *Continuum*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1212/CON.0000000000001090",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1212/CON.0000000000001090"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Abboud, H., & Probasco, J. C. (2019). *Cleve Clin J Med*. ",(0,a.jsx)("a",{href:"https://doi.org/10.3949/ccjm.86a.18129",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.3949/ccjm.86a.18129"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Varley, J., & Hacohen, Y. (2024). *Dev Med Child Neurol*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1111/dmcn.15682",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1111/dmcn.15682"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Lee, R. Y., & Pr\xfcss, H. (2025). *Trends in Neurosciences*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/j.tins.2025.04.001",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/j.tins.2025.04.001"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key findings on Limbic Encephalitis based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"http://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on July 4, 2025. Generated with Gemini."]})]})]}),cvst_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Cerebral Venous Sinus Thrombosis ",(0,a.jsx)(ej,{children:"(CVST)"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"A Comprehensive Briefing on a Rare Cerebrovascular Condition"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eg,{path:"M9.813 15.904L9 18.75l-.813-2.846a4.5 4.5 0 00-3.09-3.09L2.25 12l2.846-.813a4.5 4.5 0 003.09-3.09L9 5.25l.813 2.846a4.5 4.5 0 003.09 3.09L15.75 12l-2.846.813a4.5 4.5 0 00-3.09 3.09z"}),(0,a.jsx)("h2",{className:"text-xl font-bold text-foreground",children:"1. Epidemiology and Risk Factors"})]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"space-y-4",children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground",children:"CVST is an uncommon cause of stroke (0.5-1% of cases), disproportionately affecting young adults (mean age 35-40) and women (up to 75% of cases), largely due to hormonal factors."}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Key Risk Factors:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsx)("li",{children:"**Pregnancy & Puerperium:** Accounts for ~20% of cases, with risk heightened by procoagulant changes."}),(0,a.jsx)("li",{children:"**Hormonal Therapy:** Increases odds nearly 8-fold."}),(0,a.jsx)("li",{children:"**Infections:** Head and neck infections are common contributors."}),(0,a.jsx)("li",{children:"**Thrombophilias:** Genetic and acquired conditions like Factor V Leiden."}),(0,a.jsx)("li",{children:"**Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT):** A rare complication of adenovirus-based COVID-19 vaccines."})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Common Contributing Factors"}),(0,a.jsx)(p.BT,{children:"Approximate percentage distribution of key risk factors in studied cohorts."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:ey,className:"min-h-[200px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(m.r,{children:[(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{hideLabel:!0})}),(0,a.jsx)(x.Fq,{data:ef,dataKey:"value",nameKey:"name",cx:"50%",cy:"50%",outerRadius:80,label:!0,children:ef.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eg,{path:"M12 9.75v6.75m0 0l-3-3m3 3l3-3m-8.25 6a4.5 4.5 0 01-1.41-8.775 5.25 5.25 0 0110.233-2.33 3 3 0 013.758 3.848A3.752 3.752 0 0118 19.5H6.75z"}),(0,a.jsx)("h2",{className:"text-xl font-bold text-foreground",children:"2. Clinical Presentation"})]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground mb-2",children:"Presentation is highly variable, with a subacute onset (2 days to 1 month) being most common (50-60% of cases)."}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Headache (~90%):"})," Most common symptom, often progressive and worsens when lying down."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Seizures (~40%):"})," Far more frequent than in arterial stroke."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Focal Neurological Deficits (20-50%):"})," Hemiparesis, aphasia, visual loss."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Altered Mental Status (up to 45%):"})," Can range from lethargy to deep coma."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Visual Disturbances:"})," Papilledema, vision loss, and diplopia."]})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eg,{path:"M21 21l-5.197-5.197m0 0A7.5 7.5 0 105.196 5.196a7.5 7.5 0 0010.607 10.607z"}),(0,a.jsx)("h2",{className:"text-xl font-bold text-foreground",children:"3. Diagnosis"})]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("p",{className:"text-base text-muted-foreground mb-2",children:"Due to non-specific symptoms, neuroimaging is essential for an accurate and early diagnosis."}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"MRI with MRV:"})," The modality of choice and gold standard. Allows direct visualization of the thrombus and parenchymal lesions."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"CT with CTV:"})," A reliable alternative when MRI is unavailable or contraindicated. Non-contrast CT can be normal in 25-30% of cases."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"D-dimer:"})," Suggested before imaging in suspected acute cases; high sensitivity (89.1%)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"PF4 Antibodies:"})," Recommended for suspected Vaccine-Induced Immune Thrombotic Thrombocytopenia."]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eg,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 11-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),(0,a.jsx)("h2",{className:"text-xl font-bold text-foreground",children:"4. Treatment and Management"})]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Anticoagulation"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"The cornerstone of treatment, even with intracranial hemorrhage."}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-2 space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Initial:"})," Low-Molecular-Weight Heparin (LMWH) is preferred."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Long-Term:"})," Transition to oral anticoagulants (VKAs or DOACs). DOACs are a safe and effective alternative."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Duration:"})," 3-12 months for transient risks; may be indefinite for chronic conditions."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Pregnancy:"})," LMWH is recommended throughout pregnancy and postpartum."]})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Other Interventions"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Endovascular Treatment (EVT):"})," Reserved as a rescue therapy for patients with clinical deterioration; no clear benefit over standard anticoagulation shown."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Decompressive Craniectomy:"})," A lifesaving approach for patients with severe swelling and impending herniation."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Antiepileptic Drugs:"})," Suggested for patients with supratentorial lesions and seizures to prevent recurrence."]})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eg,{path:"M3.75 12h16.5m-16.5 3.75h16.5M3.75 19.5h16.5M5.625 4.5h12.75a1.875 1.875 0 010 3.75H5.625a1.875 1.875 0 010-3.75z"}),(0,a.jsx)("h2",{className:"text-xl font-bold text-foreground",children:"5. Complications and Outcomes"})]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Functional Recovery Over Time"}),(0,a.jsx)(p.BT,{children:"Percentage of patients with no or mild disability (mRS 0-1)."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:eb,className:"min-h-[200px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:ev,children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"stage",tickLine:!1,tickMargin:10,axisLine:!1}),(0,a.jsx)(S.h,{unit:"%"}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"mRS_0_1",fill:eb.mRS_0_1.color,radius:[4,4,0,0],barSize:40})]})})})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"Mortality Rates by Subgroup"}),(0,a.jsx)(p.BT,{children:"Mortality varies significantly based on cause and context."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:ek,className:"min-h-[200px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:eN,layout:"vertical",children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(S.h,{dataKey:"name",type:"category",tickLine:!1,tickMargin:10,axisLine:!1,width:100,tick:{fontSize:12}}),(0,a.jsx)(R.W,{dataKey:"rate",type:"number",unit:"%"}),(0,a.jsx)(A,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"rate",radius:[0,4,4,0],barSize:30,children:eN.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eg,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),(0,a.jsx)("h2",{className:"text-xl font-bold text-foreground",children:"Sources"})]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-xs text-muted-foreground columns-1 md:columns-2",children:[(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Algahtani, H., et al. (2022). *Brain Circulation*. ",(0,a.jsx)("a",{href:"https://doi.org/10.4103/bc.bc_50_22",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.4103/bc.bc_50_22"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Doggalli, N., et al. (2025). *Cureus*. ",(0,a.jsx)("a",{href:"https://doi.org/10.7759/cureus.84719",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.7759/cureus.84719"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Ferro, J. M., et al. (2017). *European Journal of Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1111/ene.13381",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1111/ene.13381"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Furie, K. L., et al. (2021). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STROKEAHA.121.035564",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STROKEAHA.121.035564"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Khan, M. W. A., et al. (2020). *Cureus*. ",(0,a.jsx)("a",{href:"https://doi.org/10.7759/cureus.12221",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.7759/cureus.12221"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Saposnik, G., et al. (2024). *Stroke*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1161/STR.0000000000000456",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1161/STR.0000000000000456"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Sitthilok, P., et al. (2025). *PLoS ONE*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1371/journal.pone.0316849",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1371/journal.pone.0316849"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key findings on Cerebral Venous Sinus Thrombosis (CVST) based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on July 31, 2025. Generated with Gemini."]})]})]}),sammpis_trial_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["A Critical Analysis of the ",(0,a.jsx)(eA,{children:"SAMMPRIS Trial"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground max-w-4xl mx-auto",children:"An interactive deconstruction of the study that redefined treatment for symptomatic intracranial stenosis, exploring its methodological and technological critiques."})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 gap-6",children:[(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{className:"items-center",children:[(0,a.jsx)(p.ZB,{className:"text-xl",children:"The Unexpected Outcome: Intervention vs. Medication"}),(0,a.jsx)(p.BT,{className:"text-center",children:"The SAMMPRIS trial was stopped prematurely as endovascular therapy (PTAS) performed significantly worse than Aggressive Medical Management (AMM) alone."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:eI,className:"h-[250px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:"100%",children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:ew,layout:"vertical",margin:{left:10,right:20},children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(R.W,{type:"number",unit:"%"}),(0,a.jsx)(S.h,{dataKey:"name",type:"category",width:220,tick:{fontSize:12}}),(0,a.jsx)(A,{cursor:{fill:"hsl(var(--muted))"},content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"value",name:"Primary Endpoint (Stroke or Death at 30 days)",radius:[0,4,4,0],barSize:30,children:ew.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h2",{className:"text-2xl font-bold text-foreground text-center mb-6 mt-4",children:"Deconstructing the Result: Key Criticisms"}),(0,a.jsxs)("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{className:"text-lg text-primary",children:"1. Excessive Periprocedural Risk"}),(0,a.jsx)(p.BT,{children:"The central critique is the high complication rate of the PTAS procedure, suggesting acute, procedure-related failures."})]}),(0,a.jsxs)(p.Wu,{className:"space-y-4",children:[(0,a.jsxs)("div",{className:"text-center",children:[(0,a.jsx)("p",{className:"text-4xl font-extrabold text-destructive",children:"75%"}),(0,a.jsx)("p",{className:"text-sm text-muted-foreground",children:"of primary endpoint events in the PTAS arm occurred within 24 hours."})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{className:"items-center p-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"Composition of 30-Day Events (PTAS Arm)"})}),(0,a.jsx)(p.Wu,{className:"p-0",children:(0,a.jsx)(N,{config:eR,className:"h-[180px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:"100%",children:(0,a.jsxs)(m.r,{children:[(0,a.jsx)(A,{content:(0,a.jsx)(C,{hideLabel:!0})}),(0,a.jsx)(x.Fq,{data:eM,dataKey:"value",nameKey:"name",cx:"50%",cy:"50%",innerRadius:40,outerRadius:70,label:!0,children:eM.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{className:"text-lg text-primary",children:"2. Selection Bias & Delayed Randomization"}),(0,a.jsx)(p.BT,{children:"A central review before randomization led to an average delay of 7 days, likely filtering out high-risk patients who failed medical therapy early, skewing results in favor of the medical arm."})]}),(0,a.jsx)(p.Wu,{className:"flex flex-col justify-center items-center h-full",children:(0,a.jsxs)("div",{className:"w-full space-y-3 p-2 border border-border/50 rounded-lg bg-muted/30",children:[(0,a.jsx)("div",{className:"bg-card p-2 rounded-lg text-center shadow-sm",children:(0,a.jsx)("p",{className:"font-semibold text-foreground text-sm",children:"Qualifying Ischemic Event"})}),(0,a.jsx)("div",{className:"text-xl font-bold text-muted-foreground text-center",children:"▼"}),(0,a.jsxs)("div",{className:"bg-card p-2 rounded-lg text-center shadow-sm",children:[(0,a.jsx)("p",{className:"font-semibold text-foreground text-sm",children:"Central Angiography Review"}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground",children:"(Average 7 Day Delay)"})]}),(0,a.jsx)("div",{className:"text-sm font-semibold text-destructive my-1 text-center p-2 border-2 border-dashed border-destructive/50 rounded-md",children:"→ Patients with Early Medical Failure Excluded"}),(0,a.jsx)("div",{className:"text-xl font-bold text-muted-foreground text-center",children:"▼"}),(0,a.jsxs)("div",{className:"bg-green-500/10 p-2 rounded-lg text-center shadow-sm",children:[(0,a.jsx)("p",{className:"font-semibold text-green-800 dark:text-green-300 text-sm",children:"Randomization"}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground",children:"(Cohort of more stable patients)"})]})]})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{className:"text-lg text-primary",children:"3. The Perforator Stroke Problem"}),(0,a.jsx)(p.BT,{children:"A high proportion of procedural strokes were lacunar (perforating) infarcts, likely caused by plaque displacement—a risk without a corresponding benefit."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{className:"items-center p-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"Type of Procedural Ischemic Strokes"})}),(0,a.jsx)(p.Wu,{className:"p-0",children:(0,a.jsx)(N,{config:eT,className:"h-[180px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:"100%",children:(0,a.jsxs)(m.r,{children:[(0,a.jsx)(A,{content:(0,a.jsx)(C,{hideLabel:!0})}),(0,a.jsx)(x.Fq,{data:eS,dataKey:"value",nameKey:"name",cx:"50%",cy:"50%",outerRadius:70,label:!0,children:eS.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{className:"text-lg text-primary",children:"4. Technical & Device-Related Flaws"}),(0,a.jsx)(p.BT,{children:"Issues with sizing methodology may have led to vessel 'oversizing,' contributing to a high rate of Intracranial Hemorrhage (ICH), especially in smaller vessels."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{className:"items-center p-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"ICH Risk by Pre-Stent Vessel Diameter"})}),(0,a.jsx)(p.Wu,{className:"p-0",children:(0,a.jsx)(N,{config:eB,className:"h-[180px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:"100%",children:(0,a.jsxs)(I.E,{data:eP,children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"name",tick:{fontSize:10}}),(0,a.jsx)(S.h,{unit:"%",domain:[0,12]}),(0,a.jsx)(A,{cursor:{fill:"hsl(var(--muted))"},content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"value",name:"ICH Risk",radius:[4,4,0,0],barSize:40,children:eP.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"text-center",children:[(0,a.jsx)(p.aR,{children:(0,a.jsx)(p.ZB,{className:"text-xl",children:"Conclusion: Reinterpreting the Evidence"})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("p",{className:"text-sm text-muted-foreground max-w-4xl mx-auto",children:"The SAMMPRIS outcome is now widely interpreted not as a definitive failure of endovascular revascularization, but as a failure of a specific, early-generation technology combined with flawed patient selection. The trial's legacy is driving research toward identifying high-risk subgroups and developing safer technologies."})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eC,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"References"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-xs text-muted-foreground",children:[(0,a.jsx)("li",{className:"break-inside-avoid",children:"Chimowitz, M. I., et al. (2011). Stenting versus aggressive medical therapy for intracranial arterial stenosis. *New England Journal of Medicine*, *365*(11), 993–1003."}),(0,a.jsx)("li",{className:"break-inside-avoid",children:"Abou-Chebl, A., & Steinmetz, H. (2012). Critique of “Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis” by Chimowitz et al. *Stroke*, *43*(2), 616–620."})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on October 2, 2025. Generated with Gemini."]})]})]}),cerebral_microbleeds_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Cerebral Microbleeds: ",(0,a.jsx)(eH,{children:"What Are They Telling Us?"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"A clinician's guide to the differential diagnosis of tiny brain bleeds based on MRI findings. \uD83E\uDDE0"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eD,{path:"M21 21l-5.197-5.197m0 0A7.5 7.5 0 105.196 5.196a7.5 7.5 0 0010.607 10.607z"}),"What are Cerebral Microbleeds?"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("p",{className:"text-muted-foreground",children:'Tiny, dot-like deposits of old blood (hemosiderin). They appear as "black dots" on specific MRI sequences like SWI and T2*-GRE.'})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2 text-center",children:[(0,a.jsx)(p.aR,{children:(0,a.jsx)(p.ZB,{className:"text-xl",children:"The Golden Rule: Location is Everything"})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("p",{className:"text-muted-foreground",children:"The anatomical distribution of microbleeds is the **most important clue** to their underlying cause. We separate them into two main patterns: **Lobar** vs. **Deep**."})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eD,{path:"M12 18v-5.25m0 0a6.01 6.01 0 001.5-.189m-1.5.189a6.01 6.01 0 01-1.5-.189m3.75 7.478a12.06 12.06 0 01-4.5 0m3.75 2.311a.75.75 0 01-1.06 0l-1-1a.75.75 0 011.06-1.06l.22.22a.75.75 0 001.06 0l.22-.22a.75.75 0 011.06 1.06l-1 1z"}),"A Tale of Two Patterns: The Most Common Culprits"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6 mt-4",children:[(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{className:"text-lg text-primary",children:"Hypertensive Arteriopathy"}),(0,a.jsx)(p.BT,{children:"The #1 overall cause of microbleeds."})]}),(0,a.jsxs)(p.Wu,{className:"text-sm space-y-2",children:[(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Prevalence:"})," Found in ",(0,a.jsx)("strong",{children:"50-80%"})," of patients with a hypertensive brain hemorrhage."]}),(0,a.jsx)("p",{className:"font-semibold text-destructive",children:"LOCATION: DEEP & INFRATENTORIAL"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-muted-foreground",children:[(0,a.jsx)("li",{children:"Basal Ganglia"}),(0,a.jsx)("li",{children:"Thalamus"}),(0,a.jsx)("li",{children:"Brainstem (Pons)"}),(0,a.jsx)("li",{children:"Cerebellum"})]}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Mechanism:"})," Damage to small, perforating arteries from chronic high blood pressure."]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{className:"text-lg text-secondary",children:"Cerebral Amyloid Angiopathy (CAA)"}),(0,a.jsx)(p.BT,{children:"The #1 cause of *strictly lobar* microbleeds in the elderly."})]}),(0,a.jsxs)(p.Wu,{className:"text-sm space-y-2",children:[(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Prevalence:"})," Found in up to ",(0,a.jsx)("strong",{children:"80%"})," of patients with Alzheimer's Disease."]}),(0,a.jsx)("p",{className:"font-semibold text-blue-600 dark:text-blue-400",children:"LOCATION: LOBAR (CORTICAL-SUBORTICAL)"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-muted-foreground",children:[(0,a.jsx)("li",{children:"Parietal Lobes"}),(0,a.jsx)("li",{children:"Occipital Lobes"}),(0,a.jsx)("li",{className:"italic",children:"(Crucially, spares the deep structures)"})]}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Mechanism:"})," Beta-amyloid protein buildup weakening the walls of cortical blood vessels."]})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eD,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 11-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"Beyond the Basics: Other Potential Causes (<10%)"]}),(0,a.jsx)(p.BT,{children:"Consider these in specific clinical contexts. \uD83D\uDD2C"})]}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 sm:grid-cols-2 lg:grid-cols-3 gap-4",children:[(0,a.jsxs)("div",{className:"bg-muted/50 p-4 rounded-lg text-center",children:[(0,a.jsx)(eD,{path:"M9 12.75l3 3m0 0l3-3m-3 3v-7.5M21 12a9 9 0 11-18 0 9 9 0 0118 0z",className:"mx-auto"}),(0,a.jsx)("h3",{className:"font-semibold mt-2",children:"CADASIL"}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-1",children:"Hereditary small vessel disease. Look for CMBs in anterior temporal lobes & external capsule. Affects 30-70% of patients."})]}),(0,a.jsxs)("div",{className:"bg-muted/50 p-4 rounded-lg text-center",children:[(0,a.jsx)(eD,{path:"M12 3v2.25m6.364.386l-1.591 1.591M21 12h-2.25m-.386 6.364l-1.591-1.591M12 18.75V21m-4.773-4.227l-1.591 1.591M5.25 12H3m4.227-4.773L5.636 5.636M15.75 12a3.75 3.75 0 11-7.5 0 3.75 3.75 0 017.5 0z",className:"mx-auto"}),(0,a.jsx)("h3",{className:"font-semibold mt-2",children:"Radiation Vasculopathy"}),(0,a.jsxs)("p",{className:"text-xs text-muted-foreground mt-1",children:["Late effect of radiation therapy. CMBs are strictly within the radiation field. Develops in ",">","50% of patients."]})]}),(0,a.jsxs)("div",{className:"bg-muted/50 p-4 rounded-lg text-center",children:[(0,a.jsx)(eD,{path:"M21 8.25c0-2.485-2.099-4.5-4.688-4.5-1.935 0-3.597 1.126-4.312 2.733-.715-1.607-2.377-2.733-4.313-2.733C5.1 3.75 3 5.765 3 8.25c0 7.22 9 12 9 12s9-4.78 9-12z",className:"mx-auto"}),(0,a.jsx)("h3",{className:"font-semibold mt-2",children:"Embolic Showers"}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-1",children:"Acute/subacute finding. Scattered CMBs in the context of septic emboli (endocarditis) or fat emboli (fracture)."})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eD,{path:"M3.75 6.75h16.5M3.75 12h16.5m-16.5 5.25h16.5"}),"At a Glance: Key Differentiators"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("div",{className:"overflow-x-auto",children:(0,a.jsxs)("table",{className:"w-full text-sm text-left",children:[(0,a.jsx)("thead",{className:"text-xs uppercase bg-muted/50",children:(0,a.jsxs)("tr",{children:[(0,a.jsx)("th",{scope:"col",className:"px-6 py-3",children:"Cause"}),(0,a.jsx)("th",{scope:"col",className:"px-6 py-3",children:"Typical Location"}),(0,a.jsx)("th",{scope:"col",className:"px-6 py-3",children:"Key Clinical Context"})]})}),(0,a.jsxs)("tbody",{children:[(0,a.jsxs)("tr",{className:"border-b",children:[(0,a.jsx)("th",{scope:"row",className:"px-6 py-4 font-medium text-foreground whitespace-nowrap",children:"Hypertension"}),(0,a.jsx)("td",{className:"px-6 py-4",children:"**Deep** (Basal Ganglia, Brainstem)"}),(0,a.jsx)("td",{className:"px-6 py-4",children:"Chronic High Blood Pressure"})]}),(0,a.jsxs)("tr",{className:"border-b",children:[(0,a.jsx)("th",{scope:"row",className:"px-6 py-4 font-medium text-foreground whitespace-nowrap",children:"CAA"}),(0,a.jsx)("td",{className:"px-6 py-4",children:"**Lobar** (Cortical-Subcortical)"}),(0,a.jsx)("td",{className:"px-6 py-4",children:"Older Age, Cognitive Decline"})]})]})]})})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eD,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-xs text-muted-foreground columns-1",children:[(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Greenberg, S. M., Vernooij, M. W., Cordonnier, C., Viswanathan, A., Al-Shahi Salman, R., Warach, S., & van Buchem, M. A. (2009). Cerebral microbleeds: a guide to detection and interpretation. *The Lancet Neurology*, *8*(2), 165–174. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/S1474-4422(09)70013-4",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/S1474-4422(09)70013-4"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Charidimou, A., Kakar, P., & Werring, D. J. (2012). Cerebral microbleeds and recurrent stroke risk: a meta-analysis. *Journal of neurology, neurosurgery, and psychiatry*, *83*(6), 595–601. ",(0,a.jsx)("a",{href:"https://doi.org/10.1136/jnnp-2011-301319",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1136/jnnp-2011-301319"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Shoamanesh, A., Kwok, C. S., & Benavente, O. (2016). Cerebral microbleeds: a review of their prevalence and clinical significance. *Expert review of neurotherapeutics*, *16*(3), 293–306. ",(0,a.jsx)("a",{href:"https://doi.org/10.1586/14737175.2016.1147570",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1586/14737175.2016.1147570"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Pasi, M., Charidimou, A., Boulouis, G., Auriel, E., van Etten, E. S., Haley, K., ... & Greenberg, S. M. (2018). Mixed-location cerebral microbleeds and risk of stroke. *Neurology*, *90*(11), e941-e949. ",(0,a.jsx)("a",{href:"https://doi.org/10.1212/WNL.0000000000005115",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1212/WNL.0000000000005115"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Akoudad, S., Wolters, F. J., Viswanathan, A., de Bruijn, R. F., van der Lugt, A., Hofman, A., ... & Vernooij, M. W. (2016). Association of cerebral microbleeds with mortality, stroke, and dementia. *JAMA neurology*, *73*(8), 991-998. ",(0,a.jsx)("a",{href:"https://doi.org/10.1001/jamaneurol.2016.1017",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1001/jamaneurol.2016.1017"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key findings on Cerebral Microbleeds based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on October 3, 2025. Generated with Gemini."]})]})]}),cerebral_cavernous_malformation_infographic:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Cerebral Cavernous ",(0,a.jsx)(eL,{children:"Malformation (CCM)"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"Integrated Perspectives from Neuroradiology, Neurosurgery, and Neurology"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 lg:grid-cols-3 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2 lg:col-span-3",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eW,{path:"M3.75 3.75v4.5m0-4.5h4.5m-4.5 0L9 9M3.75 20.25v-4.5m0 4.5h4.5m-4.5 0L9 15M20.25 3.75h-4.5m4.5 0v4.5m0-4.5L15 9m5.25 11.25h-4.5m4.5 0v-4.5m0 4.5L15 15"}),"1. Definition & Clinical Context"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Cerebral Cavernous Malformation (CCM)"}),(0,a.jsxs)("p",{className:"text-muted-foreground text-base mt-1",children:["A CCM is a low-flow vascular lesion composed of dilated, weak-walled sinusoidal channels. It's the second most common cerebral vascular anomaly, with a prevalence of about ",(0,a.jsx)("strong",{className:"text-primary",children:"0.5% in the general population (1 in 200 people)"}),". While many are asymptomatic, CCMs can cause seizures, headaches, focal neurological deficits, or intracranial hemorrhage."]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"The Most Common Anomaly: DVA"}),(0,a.jsxs)("p",{className:"text-muted-foreground text-base mt-1",children:["The ",(0,a.jsx)("strong",{className:"text-primary",children:"Developmental Venous Anomaly (DVA)"})," is the most common cerebral vascular malformation. It is a benign variant of venous drainage. CCMs are frequently associated with a DVA, a crucial consideration for surgical planning to avoid venous infarction if the DVA is resected."]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2 lg:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eW,{path:"M9 4.5v15m6-15v15m-10.875 0h15.75c.621 0 1.125-.504 1.125-1.125V5.625c0-.621-.504-1.125-1.125-1.125H4.125C3.504 4.5 3 5.004 3 5.625v12.75c0 .621.504 1.125 1.125 1.125z"}),"2. Neuroradiological Diagnosis with MRI"]})}),(0,a.jsxs)(p.Wu,{className:"space-y-4",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Classic MRI Appearance of CCM"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:'CCMs have a pathognomonic "popcorn" or reticulated core of mixed signal on T2-weighted images, surrounded by a complete, dark (hypointense) halo of hemosiderin. Contrast enhancement is typically minimal or absent.'})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"The Gold Standard: SWI"}),(0,a.jsx)("p",{className:"text-base text-muted-foreground mt-1",children:"Susceptibility-Weighted Imaging (SWI) is significantly more sensitive than T2* GRE for detecting CCMs. Studies show SWI detects a much higher number of lesions (152 vs. 56 in one study) and reveals microcavernomas (Type IV/V) invisible on conventional sequences."})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eW,{path:"M11.42 15.17L17.25 21A2.652 2.652 0 0021 17.25l-5.877-5.877M11.42 15.17l2.496-3.03c.317-.384.74-.626 1.208-.766M11.42 15.17l-4.654 5.654a2.652 2.652 0 01-3.752-3.752l5.654-4.654M3 3l3.59 3.59m0 0A2.652 2.652 0 019 9m7.5-3A2.652 2.652 0 0013.5 3m-3 0a2.652 2.652 0 00-3 3.59"}),"3. Molecular & Genetic Basis"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsxs)("p",{className:"text-base text-muted-foreground mb-2",children:["Familial CCM is linked to mutations in three key genes: ",(0,a.jsx)("strong",{className:"text-primary",children:"CCM1 (KRIT1)"}),", ",(0,a.jsx)("strong",{className:"text-primary",children:"CCM2 (MGC4607)"}),", and ",(0,a.jsx)("strong",{className:"text-primary",children:"CCM3 (PDCD10)"}),". These genes are vital for endothelial cell junction integrity."]}),(0,a.jsxs)("p",{className:"text-base text-muted-foreground",children:["Mutations in ",(0,a.jsx)("strong",{className:"text-destructive",children:"CCM3"})," are associated with the most severe disease form, often in children, leading to multiple lesions and recurrent hemorrhages."]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2 lg:col-span-2",children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eW,{path:"M2.25 18L9 11.25l4.306 4.307a11.95 11.95 0 015.814-5.519l2.74-1.22m0 0l-1.37-1.37m1.37 1.37l-1.586 1.585"}),"4. Natural History & Hemorrhage Risk"]}),(0,a.jsx)(p.BT,{children:"Annual Hemorrhage Risk (AHR) varies dramatically based on location and prior bleeding."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:eE,className:"min-h-[300px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:300,children:(0,a.jsxs)(I.E,{data:eZ,margin:{top:20,right:20,left:0,bottom:50},children:[(0,a.jsx)(M.d,{vertical:!1,strokeDasharray:"3 3"}),(0,a.jsx)(R.W,{dataKey:"name",tick:{fontSize:10},angle:-40,textAnchor:"end",height:80,interval:0}),(0,a.jsx)(S.h,{unit:"%"}),(0,a.jsx)(A,{cursor:{fill:"hsl(var(--muted)/0.3)"},content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"risk",name:"Annual Risk",radius:[4,4,0,0],barSize:40,children:eZ.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},e.name))})]})})})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsx)(p.ZB,{children:"5. 5-Year Accumulated ICH Risk"}),(0,a.jsx)(p.BT,{children:"Based on location and initial presentation."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)(N,{config:eF,className:"min-h-[300px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:300,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:eO,margin:{top:10,right:10,left:-20,bottom:50},children:[(0,a.jsx)(M.d,{vertical:!1,strokeDasharray:"3 3"}),(0,a.jsx)(R.W,{dataKey:"name",tick:{fontSize:10},angle:-40,textAnchor:"end",height:80,interval:0}),(0,a.jsx)(S.h,{unit:"%"}),(0,a.jsx)(A,{cursor:{fill:"hsl(var(--muted)/0.3)"},content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"risk",name:"5-Year Risk",fill:"var(--color-risk)",radius:[4,4,0,0],barSize:50})]})})})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2 lg:col-span-3",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eW,{path:"M19.5 12c0-1.232-.046-2.453-.138-3.662a4.006 4.006 0 00-3.7-3.7 48.678 48.678 0 00-7.324 0 4.006 4.006 0 00-3.7 3.7c-.092 1.21-.138 2.43-.138 3.662v1.562a4.006 4.006 0 003.7 3.7c1.846.053 3.695.085 5.568 0a4.006 4.006 0 003.7-3.7v-1.562z"}),"6. Therapeutic Management"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 sm:grid-cols-2 lg:grid-cols-3 gap-4 text-sm",children:[(0,a.jsxs)("div",{className:"bg-muted/50 p-4 rounded-lg border",children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Observation"}),(0,a.jsx)("p",{className:"text-muted-foreground mt-1",children:"Appropriate for asymptomatic lesions, especially those discovered incidentally, given the very low annual hemorrhage risk (0.08%)."})]}),(0,a.jsxs)("div",{className:"bg-muted/50 p-4 rounded-lg border",children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Microsurgery"}),(0,a.jsx)("p",{className:"text-muted-foreground mt-1",children:"The only curative option, immediately eliminating re-bleed risk. Indicated for symptomatic CCMs that have bled or cause refractory seizures. Total resection is achieved in >98% of pediatric cases."})]}),(0,a.jsxs)("div",{className:"bg-muted/50 p-4 rounded-lg border",children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Stereotactic Radiosurgery (SRS)"}),(0,a.jsx)("p",{className:"text-muted-foreground mt-1",children:"An alternative for deep or eloquent lesions. Hemorrhage risk reduction begins ~2 years post-treatment. PND rates are comparable to microsurgery for brainstem CCMs."})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2 lg:col-span-3",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eW,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-sm text-muted-foreground columns-1 md:columns-2",children:[(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Al-Shahi Salman, R., et al. (2016). *The Lancet Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1016/S1474-4422(15)00164-7",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1016/S1474-4422(15)00164-7"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Goldstein, H. E., et al. (2022). *Neurosurgery*. ",(0,a.jsx)("a",{href:"https://doi.org/10.1227/neu.0000000000001994",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.1227/neu.0000000000001994"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Ren, Y., et al. (2023). *Frontiers in Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.3389/fneur.2023.1168812",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.3389/fneur.2023.1168812"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Scimone, C., et al. (2022). *Cancers*. ",(0,a.jsx)("a",{href:"https://doi.org/10.3390/cancers14092265",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.3390/cancers14092265"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Zhang, C., et al. (2020). *Frontiers in Neurology*. ",(0,a.jsx)("a",{href:"https://doi.org/10.3389/fneur.2020.00591",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI: 10.3389/fneur.2020.00591"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key findings on Cerebral Cavernous Malformation (CCM) based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on October 8, 2025. Generated with Gemini."]})]})]}),intracranial_hemorrhage_infographic:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Intracranial Hemorrhage: ",(0,a.jsx)(e_,{children:"A Breakdown by Etiology"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"Classification and Prevalence of Spontaneous and Traumatic Causes"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eG,{path:"M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z"}),"1. Spontaneous Intracerebral Hemorrhage (ICH)"]}),(0,a.jsx)(p.BT,{children:"Defined as non-traumatic bleeding within the brain tissue (parenchyma), it is the deadliest form of stroke. Spontaneous ICH is classified into primary causes (from small vessel disease) and secondary causes (from structural anomalies or systemic issues)."})]}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("div",{className:"grid grid-cols-1 lg:grid-cols-3 gap-6",children:[(0,a.jsxs)("div",{className:"lg:col-span-1",children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground mb-2",children:"Key Etiologies:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-sm text-muted-foreground space-y-2",children:[(0,a.jsxs)("li",{className:"font-semibold text-primary",children:["Hypertensive Arteriopathy: ",(0,a.jsx)("span",{className:"font-normal text-muted-foreground",children:"Most common cause. Weakens deep-penetrating arteries due to chronic hypertension."})]}),(0,a.jsxs)("li",{className:"font-semibold",style:{color:"hsl(var(--chart-2))"},children:["Coagulopathy / Antithrombotic Use: ",(0,a.jsx)("span",{className:"font-normal text-muted-foreground",children:"Increasingly common due to widespread use of anticoagulants (e.g., warfarin) and antiplatelet drugs."})]}),(0,a.jsxs)("li",{className:"font-semibold",style:{color:"hsl(var(--chart-3))"},children:["Cerebral Amyloid Angiopathy (CAA): ",(0,a.jsx)("span",{className:"font-normal text-muted-foreground",children:"Protein deposits weakening cortical vessels. Leading cause of lobar (superficial) ICH in the elderly."})]}),(0,a.jsxs)("li",{className:"font-semibold",style:{color:"hsl(var(--chart-4))"},children:["Vascular Malformations: ",(0,a.jsx)("span",{className:"font-normal text-muted-foreground",children:"AVMs are the leading cause of ICH in adults younger than 35."})]}),(0,a.jsx)("li",{children:(0,a.jsx)("span",{className:"font-normal text-muted-foreground",children:"Undetermined / Other: Accounts for 5% to 18% of cases after initial investigation."})})]})]}),(0,a.jsx)("div",{className:"lg:col-span-2",children:(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{className:"p-2 pt-0",children:[(0,a.jsx)(p.ZB,{className:"text-lg",children:"Prevalence of Spontaneous ICH Etiologies"}),(0,a.jsx)(p.BT,{children:"Estimated percentage composition of underlying causes."})]}),(0,a.jsx)(p.Wu,{className:"p-0",children:(0,a.jsx)(N,{config:eK,className:"min-h-[250px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:250,children:(0,a.jsxs)(m.r,{margin:{top:10,right:10,bottom:10,left:10},children:[(0,a.jsx)(j.m,{cursor:{fill:"transparent"},content:(0,a.jsx)(C,{})}),(0,a.jsx)(g.s,{layout:"horizontal",verticalAlign:"bottom",align:"center",iconType:"circle",wrapperStyle:{paddingTop:"10px"}}),(0,a.jsx)(x.Fq,{data:ez,dataKey:"value",nameKey:"name",cx:"50%",cy:"50%",outerRadius:100,labelLine:!1,label:e=>{let{name:s,percent:r}=e;return"".concat((100*r).toFixed(0),"%")},paddingAngle:3,children:ez.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")"),stroke:"hsl(var(--background))",strokeWidth:2},"cell-".concat(e.key)))})]})})})})]})})]})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eG,{path:"M21 12a9 9 0 11-18 0 9 9 0 0118 0z"}),"2. Subarachnoid Hemorrhage (SAH)"]}),(0,a.jsx)(p.BT,{children:"Bleeding into the subarachnoid space. Trauma is the most common cause overall, but spontaneous SAH is dominated by aneurysms."})]}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)(N,{config:eq,className:"min-h-[250px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:250,children:(0,a.jsxs)(m.r,{children:[(0,a.jsx)(j.m,{cursor:{fill:"transparent"},content:(0,a.jsx)(C,{})}),(0,a.jsx)(g.s,{iconType:"circle"}),(0,a.jsx)(x.Fq,{data:eV,dataKey:"value",nameKey:"name",cx:"50%",cy:"50%",innerRadius:60,outerRadius:90,paddingAngle:2,children:eV.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")"),stroke:"hsl(var(--background))",strokeWidth:2},"cell-".concat(e.key)))})]})})}),(0,a.jsx)("p",{className:"text-sm text-center mt-2 text-muted-foreground",children:"85% of spontaneous cases are due to ruptured aneurysms."})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eG,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 11-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"3. Traumatic Hemorrhages & Risk Rates"]}),(0,a.jsx)(p.BT,{children:"Key rates for aneurysms and an overview of traumatic bleeds."})]}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsx)("div",{className:"flex items-center justify-center",children:(0,a.jsx)(N,{config:eU,className:"min-h-[250px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:250,children:(0,a.jsxs)(I.E,{data:eJ,layout:"vertical",children:[(0,a.jsx)(M.d,{horizontal:!1,strokeDasharray:"3 3"}),(0,a.jsx)(R.W,{type:"number",unit:"%",tickLine:!1,tickMargin:10,axisLine:!1}),(0,a.jsx)(S.h,{dataKey:"name",type:"category",tickLine:!1,width:150,tick:{fontSize:12}}),(0,a.jsx)(j.m,{cursor:{fill:"hsl(var(--muted))"},content:(0,a.jsx)(C,{})}),(0,a.jsx)(T.yP,{dataKey:"rate",radius:[4,4,0,0],barSize:25,children:eJ.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})}),(0,a.jsxs)("div",{className:"flex flex-col justify-center space-y-4",children:[(0,a.jsxs)("div",{className:"p-4 bg-destructive/10 border border-destructive/20 rounded-lg",children:[(0,a.jsx)("h4",{className:"font-bold text-destructive text-lg",children:"Subdural Hematoma (SDH)"}),(0,a.jsx)("p",{className:"text-sm text-muted-foreground mt-2",children:"Overwhelmingly **Traumatic**. Caused by tearing of **bridging veins**. Occurs in **11% to 25%** of significant head injuries."})]}),(0,a.jsxs)("div",{className:"p-4 bg-destructive/10 border border-destructive/20 rounded-lg",children:[(0,a.jsx)("h4",{className:"font-bold text-destructive text-lg",children:"Epidural Hematoma (EDH)"}),(0,a.jsx)("p",{className:"text-sm text-muted-foreground mt-2",children:"Almost exclusively **Traumatic**. Usually involves a skull fracture tearing the **middle meningeal artery**. Occurs in **2% to 10%** of head injuries."})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eG,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("ul",{className:"space-y-3 text-xs text-muted-foreground columns-1 md:columns-2",children:[{title:"Intracranial Hemorrhage: A Breakdown by Etiology, Types, Causes, and Outcomes",source:"Codman Surgical",url:"https://codmansurgical.integralife.com/intracranial-hemorrhage-types-causes-and-outcomes/"},{title:"Subdural Hematoma",source:"DynaMed",url:"https://www.dynamed.com/condition/subdural-hematoma"},{title:"Prevalence of Subdural and Epidural Hematoma in Head Trauma Patients: A Cross-sectional Study",source:"Index Copernicus",url:"https://journals.indexcopernicus.com/api/file/viewByFileId/1898106"},{title:"A case of spontaneous bilateral epidural hematoma associated with decreased coagulation factor XII activity: case report and literature review",source:"Frontiers",url:"https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1460073/full"},{title:"Epidural Hematoma",source:"StatPearls - NCBI Bookshelf",url:"https://www.ncbi.nlm.nih.gov/books/NBK518982/"},{title:"Epidural Hematoma (EDH): Symptoms, Causes & Treatment",source:"Cleveland Clinic",url:"https://my.clevelandclinic.org/health/diseases/22034-epidural-hematoma"},{title:"The importance of additional intracranial injuries in epidural hematomas: detailed clinical analysis, long-term outcome, and literature review in surgically managed epidural hematomas",source:"Frontiers",url:"#"}].map((e,s)=>(0,a.jsxs)("li",{className:"break-inside-avoid",children:[(0,a.jsx)("span",{className:"font-semibold",children:e.title})," - ",e.source,".",e.url&&"#"!==e.url&&(0,a.jsx)("a",{href:e.url,target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline ml-1",children:"[Access Link]"})]},s))})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsxs)("p",{children:["This infographic summarizes key findings on ","Intracranial Hemorrhage Etiology and Classification"," based on current literature."]}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on ","October 9, 2025",". Generated with Gemini."]})]})]}),quantitative_alcohol_cns_infographic:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Quantitative Analysis: Alcohol's Effects on the ",(0,a.jsx)(eX,{children:"Central Nervous System"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"Incidence, Prevalence, and Radiological Detection (CT/MRI)"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eY,{path:"M3.75 6.75h16.5M3.75 12h16.5m-16.5 5.25h16.5"}),"1. Executive Summary"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("p",{className:"text-base text-muted-foreground",children:["Alcohol Use Disorder (AUD) causes significant CNS morbidity. Nutritional deficiencies elevate risks for acute conditions like Wernicke Encephalopathy (WE), with a post-mortem/subclinical prevalence of ",(0,a.jsx)("strong",{className:"text-destructive",children:"12-14%"})," in chronic users, yet the classic triad appears in only ",(0,a.jsx)("strong",{className:"text-destructive",children:"16-33%"}),". MRI is the gold standard for diagnosis (WE Sensitivity: ",(0,a.jsx)("strong",{className:"text-primary",children:"53%"}),", Specificity: ",(0,a.jsx)("strong",{className:"text-primary",children:"93%"}),"), vastly outperforming CT. Chronic effects like atrophy are detectable in ",(0,a.jsx)("strong",{className:"text-primary",children:"93-100%"})," of complicated cases via MRI."]})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eY,{path:"M15.042 21.002a2.25 2.25 0 01-3.084 0 2.25 2.25 0 01-3.084 0M12 6.002v9.75m-3.111 2.553a.75.75 0 01-1.06 0l-3-3a.75.75 0 011.06-1.06l1.06 1.06 4.765-4.764a.75.75 0 111.06 1.06l-5.25 5.25-1.591 1.591z"}),"2. Wernicke-Korsakoff Syndrome (WKS)"]})}),(0,a.jsxs)(p.Wu,{className:"space-y-6",children:[(0,a.jsx)(N,{config:e$,className:"min-h-[150px] w-full",children:(0,a.jsxs)(a.Fragment,{children:[(0,a.jsx)(p.aR,{className:"p-0 mb-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"Prevalence of WKS"})}),(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:eQ,children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"name",tickLine:!1,tickMargin:10,axisLine:!1,tick:{fontSize:10}}),(0,a.jsx)(S.h,{unit:"%"}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"value",name:"Prevalence",radius:[4,4,0,0],barSize:40,children:eQ.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})]})}),(0,a.jsx)(N,{config:e1,className:"min-h-[150px] w-full",children:(0,a.jsxs)(a.Fragment,{children:[(0,a.jsx)(p.aR,{className:"p-0 mb-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"Clinical Presentation of Acute WE"})}),(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(m.r,{children:[(0,a.jsx)(j.m,{content:(0,a.jsx)(C,{hideLabel:!0})}),(0,a.jsx)(x.Fq,{data:e0,dataKey:"value",nameKey:"name",innerRadius:30,outerRadius:50,children:e0.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))}),(0,a.jsx)(g.s,{layout:"vertical",align:"right",verticalAlign:"middle"})]})})]})}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-2",children:"The high prevalence combined with low classic symptom frequency highlights a crisis of underdiagnosis. Empirical thiamine treatment is crucial."})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eY,{path:"M9 4.5v15m6-15v15m-10.875 0h15.75c.621 0 1.125-.504 1.125-1.125V5.625c0-.621-.504-1.125-1.125-1.125H4.125C3.504 4.5 3 5.004 3 5.625v12.75c0 .621.504 1.125 1.125 1.125z"}),"3. Imaging WE: MRI vs. CT"]})}),(0,a.jsxs)(p.Wu,{className:"space-y-6",children:[(0,a.jsx)(N,{config:e5,className:"min-h-[150px] w-full",children:(0,a.jsxs)(a.Fragment,{children:[(0,a.jsx)(p.aR,{className:"p-0 mb-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"MRI Diagnostic Accuracy for Acute WE"})}),(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:e2,children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"name",tickLine:!1,axisLine:!1,tick:{fontSize:10}}),(0,a.jsx)(S.h,{unit:"%"}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"value",name:"Percentage",radius:[4,4,0,0],barSize:40,children:e2.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})]})}),(0,a.jsx)(N,{config:e7,className:"min-h-[200px] w-full",children:(0,a.jsxs)(a.Fragment,{children:[(0,a.jsx)(p.aR,{className:"p-0 mb-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"Frequency of MRI Regional Findings"})}),(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:e3,layout:"vertical",margin:{left:150,right:20},children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(S.h,{dataKey:"name",type:"category",tickLine:!1,tickMargin:10,axisLine:!1,width:150,tick:{fontSize:10}}),(0,a.jsx)(R.W,{dataKey:"frequency",type:"number",unit:"%"}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"frequency",name:"Frequency",radius:[0,4,4,0],barSize:30,children:e3.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})]})}),(0,a.jsxs)("p",{className:"text-sm text-muted-foreground mt-4",children:[(0,a.jsx)("strong",{children:"CT Performance:"})," CT detected acute low-density changes in only ",(0,a.jsx)("strong",{children:"13%"})," of WE cases and is considered not useful for acute diagnosis. While CT can show chronic atrophy (53-86% in WE), MRI is superior (93-100%)."]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eY,{path:"M3.75 12h16.5m-16.5 3.75h16.5M3.75 19.5h16.5M5.625 4.5h12.75a1.875 1.875 0 010 3.75H5.625a1.875 1.875 0 010-3.75z"}),"4. MBD & ODS Quantification"]})}),(0,a.jsxs)(p.Wu,{className:"space-y-4",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Marchiafava-Bignami Disease (MBD)"}),(0,a.jsxs)("p",{className:"text-sm text-muted-foreground mt-1",children:["Extremely rare degeneration of the corpus callosum linked to chronic alcohol use and B vitamin deficiencies. Prevalence is underestimated (","<","300 reported cases pre-2001). MRI is essential for diagnosis, showing symmetrical corpus callosum lesions."]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground",children:"Osmotic Demyelination Syndrome (ODS)"}),(0,a.jsx)("p",{className:"text-sm text-muted-foreground mt-1",children:"Caused by rapid correction of chronic hyponatremia. AUD is a major risk factor (ORa: 15.27)."}),(0,a.jsx)(N,{config:e9,className:"min-h-[150px] w-full",children:(0,a.jsxs)(a.Fragment,{children:[(0,a.jsx)(p.aR,{className:"p-0 mt-2 mb-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"Association of ODS with AUD"})}),(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(m.r,{children:[(0,a.jsx)(j.m,{content:(0,a.jsx)(C,{hideLabel:!0})}),(0,a.jsx)(x.Fq,{data:e8,dataKey:"value",nameKey:"name",innerRadius:30,outerRadius:50,children:e8.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))}),(0,a.jsx)(g.s,{layout:"vertical",align:"right",verticalAlign:"middle"})]})})]})})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eY,{path:"M6.75 3v2.25M17.25 3v2.25M3 18.75V7.5a2.25 2.25 0 012.25-2.25h13.5A2.25 2.25 0 0121 7.5v11.25m-18 0A2.25 2.25 0 005.25 21h13.5A2.25 2.25 0 0021 18.75m-18 0v-7.5A2.25 2.25 0 015.25 9h13.5A2.25 2.25 0 0121 11.25v7.5"}),"5. Chronic Effects: Cerebral Atrophy"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("p",{className:"text-sm text-muted-foreground mb-4",children:"Chronic alcohol use leads to structural brain damage, primarily cerebral atrophy and white matter deficits. White matter damage is considered a defining characteristic."}),(0,a.jsx)(N,{config:e4,className:"min-h-[200px] w-full",children:(0,a.jsxs)(a.Fragment,{children:[(0,a.jsx)(p.aR,{className:"p-0 mb-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"Corpus Callosum Atrophy in AUD"})}),(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:e6,children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"name",tickLine:!1,axisLine:!1,tick:{fontSize:10}}),(0,a.jsx)(S.h,{unit:"%",domain:[0,20]}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"reduction",name:"Reduction (%)",radius:[4,4,0,0],barSize:40,children:e6.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})]})}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-2",children:"Corpus callosum atrophy directly correlates with lifetime alcohol consumption, serving as a biomarker of chronic toxicity."})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(eY,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("ul",{className:"space-y-3 text-xs text-muted-foreground columns-1 md:columns-2",children:[{title:"Wet Brain from Alcohol: Wernicke-Korsakoff Syndrome (WKS)",source:"American Addiction Centers",url:"https://americanaddictioncenters.org/alcohol/risks-effects-dangers/wernicke-korsakoff-syndrome"},{title:"Wernicke Encephalopathy",source:"DynaMed",url:"https://www.dynamed.com/condition/wernicke-encephalopathy"},{title:"The Korsakoff syndrome: clinical aspects, psychology and treatment",source:"Kopelman, M. D., et al. (2015). Alcohol and Alcoholism",url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC4728174/"},{title:"Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy",source:"Antunez, E., et al. (1998). AJR",url:"https://pubmed.ncbi.nlm.nih.gov/9763009/"},{title:"Alcohol: effects on neurobehavioral functions and the brain",source:"Oscar-Berman, M., & Marinković, K. (2007). Neuropsychology review",url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC5513685/"},{title:"Hypoperfusion of inferior frontal brain regions in abstinent alcoholics: a pilot SPECT study",source:"Gansler, D. A., et al. (2000). Journal of studies on alcohol",url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC2077939/"},{title:"Osmotic Demyelination Syndrome",source:"DynaMed",url:"https://www.dynamed.com/condition/osmotic-demyelination-syndrome"},{title:"Marchiafava-Bignami disease: a rare entity with a poor outcome",source:"Menegon, V., et al. (2008). Neurological Sciences",url:"https://pmc.ncbi.nlm.nih.gov/articles/PMC4031867/"},{title:"S\xedndrome de Wernicke-Korsakoff",source:"Family Caregiver Alliance",url:"https://www.caregiver.org/es/resource/wernicke-korsakoff-spanish/"}].map((e,s)=>(0,a.jsxs)("li",{className:"break-inside-avoid",children:[(0,a.jsx)("span",{className:"font-semibold",children:e.title})," - ",e.source,".",(0,a.jsx)("a",{href:e.url,target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline ml-1",children:"[Access Link]"})]},s))})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsxs)("p",{children:["This infographic summarizes quantitative findings on ","Quantitative Analysis: Alcohol's Effects on the Central Nervous System"," based on current literature."]}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on ","October 9, 2025",". Generated with Gemini."]})]})]}),neurocysticercosis_infographic_component:()=>(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:[(0,a.jsx)(ss,{children:"Neurocysticercosis (NCC)"}),": Radiological Aspects"]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"A Comprehensive Analysis Based on Recent Evidence"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sr,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"1. Introduction & Pathophysiology"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("p",{className:"text-muted-foreground text-base",children:["Neurocysticercosis (NCC) is the most common parasitic CNS infection globally, caused by the larval form (cysticercus) of the pork tapeworm, *Taenia solium*. It's endemic in many developing regions and a leading cause of adult-onset epilepsy (approx. 1/3 of cases in endemic areas). Humans acquire NCC by ingesting parasite eggs via the fecal-oral route. Oncospheres hatch, penetrate the intestinal wall, enter the bloodstream, and lodge primarily in the CNS (gray-white matter junction, basal ganglia, cortex). Clinical presentation depends on the ",(0,a.jsx)("strong",{className:"text-primary",children:"location, number, and evolutionary stage"})," of the cysts, which dictates the host's inflammatory response."]})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sr,{path:"M9.813 15.904L9 18.75l-.813-2.846a4.5 4.5 0 00-3.09-3.09L2.25 12l2.846-.813a4.5 4.5 0 003.09-3.09L9 5.25l.813 2.846a4.5 4.5 0 003.09 3.09L15.75 12l-2.846.813a4.5 4.5 0 00-3.09 3.09z"}),"2. Parenchymal NCC: Evolutionary Stages & Imaging"]}),(0,a.jsx)(p.BT,{children:"Imaging varies dramatically by stage (Escobar's Classification)."})]}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("div",{className:"overflow-x-auto",children:(0,a.jsxs)(se.XI,{className:"text-xs",children:[(0,a.jsx)(se.A0,{children:(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nd,{children:"Stage"}),(0,a.jsx)(se.nd,{children:"CT Findings"}),(0,a.jsx)(se.nd,{children:"MRI T1"}),(0,a.jsx)(se.nd,{children:"MRI T2"}),(0,a.jsx)(se.nd,{children:"MRI FLAIR"}),(0,a.jsx)(se.nd,{children:"MRI T1+C"}),(0,a.jsx)(se.nd,{children:"Key Feature"})]})}),(0,a.jsxs)(se.BF,{children:[(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Vesicular (Viable)"}),(0,a.jsx)(se.nA,{children:"Hypodense cyst, \xb1 dot sign (scolex)"}),(0,a.jsx)(se.nA,{children:"CSF signal cyst, iso/hyper scolex"}),(0,a.jsx)(se.nA,{children:"CSF signal cyst"}),(0,a.jsx)(se.nA,{children:"Suppressed cyst, hyper scolex"}),(0,a.jsx)(se.nA,{children:"Usually none"}),(0,a.jsx)(se.nA,{children:"Visible scolex (pathognomonic)"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Colloidal (Degenerating)"}),(0,a.jsx)(se.nA,{children:"Hyperdense content, ring enhancement, edema"}),(0,a.jsx)(se.nA,{children:"Hyperintense content"}),(0,a.jsx)(se.nA,{children:"Perilesional edema, \xb1 wall ring"}),(0,a.jsx)(se.nA,{children:"Hyperintense content & edema"}),(0,a.jsx)(se.nA,{children:"Thick, regular ring enhancement"}),(0,a.jsx)(se.nA,{children:"Intense inflammation, edema"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Granular Nodular (Involution)"}),(0,a.jsx)(se.nA,{children:"Isodense/hyperdense nodule, ↓ edema"}),(0,a.jsx)(se.nA,{children:"Isointense nodule"}),(0,a.jsx)(se.nA,{children:"Variable signal"}),(0,a.jsx)(se.nA,{children:"Variable signal"}),(0,a.jsx)(se.nA,{children:"Nodular/smaller ring enhancement"}),(0,a.jsx)(se.nA,{children:"Shrinking lesion, resolving edema"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Nodular Calcified (Scar)"}),(0,a.jsx)(se.nA,{children:"Hyperdense nodule (CT best)"}),(0,a.jsx)(se.nA,{children:"Variable, \xb1 hyperintense"}),(0,a.jsx)(se.nA,{children:"Signal void (T2*/SWI best)"}),(0,a.jsx)(se.nA,{children:"Signal void"}),(0,a.jsx)(se.nA,{children:"Usually none (\xb1 persistent enhancement)"}),(0,a.jsx)(se.nA,{children:"Calcification; may still cause seizures"})]})]})]})}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-2",children:"*Note: Coexistence of lesions in different stages is highly suggestive of NCC.*"})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sr,{path:"M12 9.75v6.75m0 0l-3-3m3 3l3-3m-8.25 6a4.5 4.5 0 01-1.41-8.775 5.25 5.25 0 0110.233-2.33 3 3 0 013.758 3.848A3.752 3.752 0 0118 19.5H6.75z"}),"3. Extraparenchymal Forms (Higher Morbidity/Mortality)"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-3 gap-4",children:[(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{className:"pb-2",children:(0,a.jsx)(p.ZB,{className:"text-base text-primary",children:"Intraventricular (7-20%)"})}),(0,a.jsxs)(p.Wu,{className:"text-sm space-y-1",children:[(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Risk:"})," Obstructive hydrocephalus, ependymitis."]}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Imaging Challenge:"})," Cysts often isointense to CSF (invisible). Look for indirect signs (hydrocephalus) or use 3D CISS/FIESTA sequences."]}),(0,a.jsx)(N,{config:si,className:"min-h-[150px] w-full mt-2",children:(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(I.E,{data:sa,layout:"vertical",margin:{left:80,right:10},children:[(0,a.jsx)(M.d,{horizontal:!1}),(0,a.jsx)(S.h,{dataKey:"name",type:"category",tickLine:!1,axisLine:!1,width:80,tick:{fontSize:9}}),(0,a.jsx)(R.W,{dataKey:"frequency",type:"number",unit:"%"}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"frequency",name:"Frequency",radius:[0,4,4,0],barSize:30,children:sa.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})}),(0,a.jsx)("p",{className:"text-xs text-center",children:"Typical locations within ventricles."})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{className:"pb-2",children:(0,a.jsx)(p.ZB,{className:"text-base text-secondary",children:"Subarachnoid/Racemose"})}),(0,a.jsxs)(p.Wu,{className:"text-sm space-y-1",children:[(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Location:"})," Basal cisterns, Sylvian fissures."]}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Morphology:"}),' "Grape-like" clusters, often without scolex.']}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Risks:"})," Hydrocephalus, chronic arachnoiditis, vasculitis, infarcts."]}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Imaging:"})," Cysts isointense to CSF. Intense leptomeningeal enhancement indicates arachnoiditis."]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{className:"pb-2",children:(0,a.jsx)(p.ZB,{className:"text-base",style:{color:"hsl(var(--chart-5))"},children:"Spinal (1-5%, Rare)"})}),(0,a.jsxs)(p.Wu,{className:"text-sm space-y-1",children:[(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Types:"})," Extramedullary-intradural (most common, often from CSF migration), Intramedullary (hematogenous)."]}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Imaging (MRI):"})," Cysts isointense to CSF, \xb1 ring enhancement. Intramedullary lesions mimic parenchymal stages."]})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sr,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 11-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"4. Advanced MRI Techniques"]})}),(0,a.jsxs)(p.Wu,{className:"space-y-3 text-sm",children:[(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"High-Resolution T2 (3D-CISS/FIESTA):"})," Essential for extraparenchymal disease. Excellent CSF-cyst contrast, improves scolex detection (visible in 93% with CISS)."]}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Diffusion-Weighted Imaging (DWI):"})," Crucial for differentiating colloidal NCC (no/mild restriction) from pyogenic abscess (marked restriction). Scolex may show restriction in early degeneration."]}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Susceptibility-Weighted Imaging (SWI):"}),' Highly sensitive for scolex (appears as a hypointense dot due to calcific corpuscles) and calcifications (shows "blooming").']}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"MR Spectroscopy (MRS):"})," Powerful for differential diagnosis. NCC shows elevated ",(0,a.jsx)("strong",{className:"text-amber-600",children:"Succinate"}),", Alanine, Lactate; low NAA, Cr; low/normal Choline. Differentiates from Tuberculomas (↑ Lipids) and Tumors (↑↑ Choline)."]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sr,{path:"M11.25 11.25l.041-.02a.75.75 0 011.063.852l-.708 2.836a.75.75 0 001.063.853l.041-.021M21 12a9 9 0 11-18 0 9 9 0 0118 0zm-9-3.75h.008v.008H12V8.25z"}),"5. Complications & Differential Diagnosis"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6 text-sm",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-destructive mb-2",children:"Complications (Mainly Extraparenchymal)"}),(0,a.jsxs)("ul",{className:"list-disc list-inside space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Vasculitis & Stroke:"})," Arachnoiditis inflames basal arteries → stenosis/occlusion → infarcts (lacunar/territorial). MRA/CTA/DSA show segmental stenosis."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Arachnoiditis & Hydrocephalus:"})," Chronic inflammation → fibrosis → CSF obstruction (communicating or non-communicating). MRI+C shows leptomeningeal enhancement."]})]})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary mb-2",children:"Differential Diagnosis (Ring-Enhancing Lesions)"}),(0,a.jsxs)("ul",{className:"list-disc list-inside space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"vs. Tuberculoma:"})," Tuberculomas often have T2 hypointense center, target sign, MRS shows high Lipids."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"vs. Pyogenic Abscess:"})," Abscess shows marked central DWI restriction (low ADC)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"vs. Tumors (Metastasis/Glioblastoma):"})," Tumors have irregular walls, more edema/mass effect, MRS shows high Choline."]})]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sr,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("ul",{className:"space-y-3 text-xs text-muted-foreground columns-1 md:columns-2",children:[{title:"Neurocysticercosis: Unwinding the radiological conundrum",source:"Bhattacharjee, S., & Shameem, M. (2024)",url:"https://doi.org/10.5114/pjr.2024.136868"},{title:"Neurocysticercosis: Radiologic-pathologic correlation",source:"Kimura-Hayama, E. T., et al. (2010)",url:"https://doi.org/10.1148/rg.306105522"},{title:"Clinical symptoms, diagnosis, and treatment of neurocysticercosis",source:"Garcia, H. H., et al. (2014)",url:"https://doi.org/10.1016/S1474-4422(14)70094-8"},{title:"Predictors of hydrocephalus in patients with neurocysticercosis",source:"Sharma, M., et al. (2016)",url:"https://doi.org/10.1016/j.jns.2016.07.039"},{title:"Neurocysticercosis: Five new things",source:"Carpio, A., et al. (2013)",url:"https://doi.org/10.1212/CPJ.0b013e31828d9f17"},{title:"From seizures to epilepsy and its substrates: Neurocysticercosis",source:"Singh, G., et al. (2013)",url:"https://doi.org/10.1111/epi.12217"},{title:"The role of conventional MR imaging sequences in the evaluation of neurocysticercosis",source:"Lucato, L. T., et al. (2007)",url:"https://doi.org/10.3174/ajnr.A0573"},{title:"MR spectroscopy in neurocysticercosis",source:"Jayakumar, P. N., et al. (2001)",url:"https://pubmed.ncbi.nlm.nih.gov/11711809/"}].map((e,s)=>(0,a.jsxs)("li",{className:"break-inside-avoid",children:[(0,a.jsx)("span",{className:"font-semibold",children:e.title})," - ",e.source,".",(0,a.jsx)("a",{href:e.url,target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline ml-1",children:"[Access Link]"})]},s))})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsxs)("p",{children:["This infographic summarizes radiological aspects of ","Neurocysticercosis (NCC)"," based on current literature."]}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on ","October 9, 2025",". Generated with Gemini."]})]})]}),oligodendroglioma_infographic_component:()=>{let{t:e}=(0,P.B)();return(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["IDH-Mutated, 1p/19q Codeleted ",(0,a.jsx)(st,{children:"Oligodendroglioma"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"An Expert Report on Epidemiology and Advanced Biomarkers"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sn,{path:"M3.75 6.75h16.5M3.75 12h16.5m-16.5 5.25h16.5"}),"1. Introduction & Molecular Context"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("p",{className:"text-base text-muted-foreground",children:["Oligodendroglioma (ODG) diagnosis was redefined by the WHO 2016/2021 classifications. It's now a ",(0,a.jsx)("strong",{className:"text-primary",children:"molecularly defined tumor"}),", requiring both an ",(0,a.jsx)("strong",{className:"text-primary",children:"IDH mutation (IDH1/IDH2)"})," and the ",(0,a.jsx)("strong",{className:"text-primary",children:"1p/19q codeletion"}),". This genetic signature predicts favorable prognosis and better response to chemoradiation compared to other gliomas. Histologically graded as WHO Grade 2 (low-grade) or Grade 3 (malignant)."]})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sn,{path:"M12 21a9.004 9.004 0 008.716-6.747M12 21a9.004 9.004 0 01-8.716-6.747M12 21c.497 0 .98-.032 1.453-.091M12 21a8.958 8.958 0 01-1.453-.091m6.264-6.656a8.973 8.973 0 01-1.453.091M3.284 14.253a8.973 8.973 0 001.453.091M12 3a9.004 9.004 0 00-8.716 6.747M12 3a9.004 9.004 0 018.716 6.747M12 3c-.497 0-.98.032-1.453-.091M12 3a8.958 8.958 0 00-1.453-.091m6.264 6.656a8.973 8.973 0 001.453-.091M3.284 9.747a8.973 8.973 0 011.453-.091"}),"2. Epidemiology & Location"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"list-disc list-inside text-base text-muted-foreground mt-1 space-y-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Incidence:"})," ~0.3 per 100,000 population/year (5-25% of all gliomas)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Peak Age:"})," Adults, commonly 20-60 years. Rare in children."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Sex:"})," Slight male predominance."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Location:"})," Typically ",(0,a.jsx)("strong",{className:"text-primary",children:"supratentorial"}),", with predilection for ",(0,a.jsx)("strong",{className:"text-primary",children:"frontal or temporal lobes"}),"."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Growth Pattern:"})," Infiltrative, involving both cortex and subcortical white matter."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Common Symptom:"})," ",(0,a.jsx)("strong",{className:"text-amber-600 dark:text-amber-400",children:"Seizures"})," due to cortical involvement."]})]})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sn,{path:"M2.25 15.75l5.159-5.159a2.25 2.25 0 013.182 0l5.159 5.159m-1.5-1.5l1.409-1.409a2.25 2.25 0 013.182 0l2.909 2.909m-18 3.75h16.5a1.5 1.5 0 001.5-1.5V6a1.5 1.5 0 00-1.5-1.5H3.75A1.5 1.5 0 002.25 6v12a1.5 1.5 0 001.5 1.5zm10.5-11.25h.008v.008h-.008V8.25zm.375 0a.375.375 0 11-.75 0 .375.375 0 01.75 0z"}),"3. Conventional Imaging Findings"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("div",{className:"overflow-x-auto",children:(0,a.jsxs)(se.XI,{className:"text-sm",children:[(0,a.jsx)(se.A0,{children:(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nd,{children:"Modality/Sequence"}),(0,a.jsx)(se.nd,{children:"Typical Sign"}),(0,a.jsx)(se.nd,{children:"Comments"})]})}),(0,a.jsxs)(se.BF,{children:[(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"CT"}),(0,a.jsxs)(se.nA,{children:["Hypodensity, ",(0,a.jsx)("strong",{className:"text-amber-600 dark:text-amber-400",children:"Intratumoral Calcifications"})]}),(0,a.jsx)(se.nA,{children:"Calcification is the classic sign; SWI is more sensitive."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"MRI T1"}),(0,a.jsx)(se.nA,{children:"Hypointense"}),(0,a.jsx)(se.nA,{children:"Reflects high water content."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"MRI T2/FLAIR"}),(0,a.jsx)(se.nA,{children:"Hyperintense, often heterogeneous"}),(0,a.jsx)(se.nA,{children:"Cortical infiltration often seen."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"MRI SWI/GRE"}),(0,a.jsx)(se.nA,{children:(0,a.jsx)("strong",{className:"text-amber-600 dark:text-amber-400",children:'"Blooming" Effect'})}),(0,a.jsx)(se.nA,{children:"Superior detection of calcifications & microhemorrhage."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"MRI T1 C+ (Gd)"}),(0,a.jsx)(se.nA,{children:"Variable Enhancement (~50%)"}),(0,a.jsxs)(se.nA,{children:[(0,a.jsx)("strong",{className:"text-destructive",children:"Low reliability for histological grading (II vs. III)"}),"."]})]})]})]})})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sn,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"4. Advanced Radiological Biomarkers"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("div",{className:"overflow-x-auto",children:(0,a.jsxs)(se.XI,{className:"text-sm",children:[(0,a.jsx)(se.A0,{children:(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nd,{children:"Technique"}),(0,a.jsx)(se.nd,{children:"Metric"}),(0,a.jsx)(se.nd,{children:"Typical Finding in ODG"}),(0,a.jsx)(se.nd,{children:"Grading Utility (II vs. III)"})]})}),(0,a.jsxs)(se.BF,{children:[(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"DWI/ADC"}),(0,a.jsx)(se.nA,{children:"ADC Value"}),(0,a.jsx)(se.nA,{children:"High (no restriction)"}),(0,a.jsx)(se.nA,{children:"Good for differentiating from high-grade astrocytomas (low ADC)."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"MRS"}),(0,a.jsx)(se.nA,{children:"Cho/NAA, Cho/Cr, Lipids"}),(0,a.jsx)(se.nA,{children:"Increased Cho/NAA; prominent lipid peak"}),(0,a.jsx)(se.nA,{children:"High Cho/Cr suggests Grade III, but overlap limits certainty. Guides biopsy."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"PWI (Perfusion)"}),(0,a.jsx)(se.nA,{children:"rCBV"}),(0,a.jsxs)(se.nA,{children:["Generally low (","<","1.5 in Grade II)"]}),(0,a.jsxs)(se.nA,{children:[(0,a.jsx)("strong",{className:"text-destructive",children:"Poor reliable correlation"}),". Not a primary marker for ODG malignancy."]})]})]})]})}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-2",children:"Unlike astrocytomas, malignancy (Grade III) in ODG often lacks markedly elevated rCBV, relying more on MRS findings and growth."})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sn,{path:"M16.023 9.348h4.992v-.001a.75.75 0 01.75.75c0 .414-.336.75-.75.75h-4.992a2.25 2.25 0 01-2.25-2.25V6.75A2.25 2.25 0 0112 4.5v-2.25c0-.414.336-.75.75-.75s.75.336.75.75V4.5a.75.75 0 00.75.75h3.037a.75.75 0 010 1.5H13.5a.75.75 0 00-.75.75V9a2.25 2.25 0 012.273-2.25zM5.25 6.75c0-.414.336-.75.75-.75H9a.75.75 0 010 1.5H6a.75.75 0 000 1.5h3a.75.75 0 010 1.5H6a.75.75 0 000 1.5h3a.75.75 0 010 1.5H6a.75.75 0 00-.75.75v1.5c0 .414-.336-.75-.75.75s-.75-.336-.75-.75v-1.5A2.25 2.25 0 015.25 9V6.75z"}),"5. Radiogenomics & Prognosis"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground mb-1",children:"Predicting 1p/19q Codeletion:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-sm text-muted-foreground space-y-1 mb-4",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{className:"text-amber-600 dark:text-amber-400",children:"Calcification:"})," Strongest morphological predictor."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{className:"text-primary",children:"Cortical Infiltration:"})," Characteristic growth pattern."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{className:"text-purple-600 dark:text-purple-400",children:"Low rCBV / High ADC:"})," Functional profile leaning towards ODG."]})]}),(0,a.jsxs)(p.Zp,{className:"mt-4",children:[(0,a.jsxs)(p.aR,{className:"p-2",children:[(0,a.jsx)(p.ZB,{className:"text-base",children:"5-Year Survival by WHO Grade"}),(0,a.jsx)(p.BT,{className:"text-xs",children:"Illustrates the significant prognostic impact of grade."})]}),(0,a.jsx)(p.Wu,{className:"p-0",children:(0,a.jsx)(N,{config:sc,className:"min-h-[150px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:sl,margin:{top:10,right:10,left:10,bottom:0},children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"grade",tickLine:!1,axisLine:!1,tick:{fontSize:10}}),(0,a.jsx)(S.h,{unit:"%",domain:[0,100]}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"survival",name:"5-Year Survival",radius:[4,4,0,0],barSize:40,children:sl.map(e=>(0,a.jsx)(u.f,{fill:sc[e.key].color},"cell-".concat(e.grade)))})]})})})})]}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-2",children:"1p/19q codeletion predicts superior survival and chemo/radiosensitivity."})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sn,{path:"M6.75 3v2.25M17.25 3v2.25M3 18.75V7.5a2.25 2.25 0 012.25-2.25h13.5A2.25 2.25 0 0121 7.5v11.25m-18 0A2.25 2.25 0 005.25 21h13.5A2.25 2.25 0 0021 18.75m-18 0v-7.5A2.25 2.25 0 015.25 9h13.5A2.25 2.25 0 0121 11.25v7.5"}),"6. Follow-up & Clinical Implications"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"list-disc list-inside text-sm text-muted-foreground mt-1 space-y-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Monitoring:"})," Regular MRI (at least annually) is crucial due to slow growth and risk of anaplastic transformation."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Signs of Progression:"})," Increased volume, new/progressive enhancement, or rising Cho/NAA ratio on MRS may indicate transformation to Grade 3."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Therapeutic Guidance:"})," MRI guides maximal safe resection. Radiogenomic profile (suggested by imaging) determines chemo/radiotherapy decisions."]})]})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sn,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("ul",{className:"space-y-3 text-xs text-muted-foreground columns-1 md:columns-2",children:[{title:"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary",source:"Louis, D. N., et al. (2021). Neuro-oncology",url:"https://doi.org/10.1093/neuonc/noab106"},{title:"Oligodendroglioma and Other IDH-Mutated Tumors: Diagnosis and Treatment",source:"National Cancer Institute",url:"https://www.cancer.gov/rare-brain-spine-tumor/tumors/oligodendroglioma"},{title:"Oligodendroglioma: a critical appraisal",source:"Wesseling, P., et al. (2015). Clinical Neuropathology",url:"https://pubmed.ncbi.nlm.nih.gov/26068995/"},{title:"Oligodendroglioma",source:"Radiopaedia.org",url:"https://radiopaedia.org/articles/oligodendroglioma"},{title:"Implication of radiological pattern in the prognosis of oligodendroglial tumors",source:"Garc\xeda‐Figueiras, R., et al. (2011). Revista de neurologia",url:"https://pubmed.ncbi.nlm.nih.gov/21448834/"},{title:"Oligodendroglioma - Symptoms and causes",source:"Mayo Clinic",url:"https://www.mayoclinic.org/diseases-conditions/oligodendroglioma/symptoms-causes/syc-20576736"},{title:"Detection of Intratumoral Calcification in Oligodendrogliomas by Susceptibility-Weighted MR Imaging",source:"Jeon, H. M., et al. (2019). Korean Journal of Radiology",url:"https://doi.org/10.3348/kjr.2019.0149"},{title:"Grading of oligodendroglial tumors of the brain with apparent diffusion coefficient, magnetic resonance spectroscopy, and dynamic susceptibility contrast imaging",source:"Kim, Y., et al. (2011). Korean Journal of Radiology",url:"https://doi.org/10.3348/kjr.2011.12.6.665"},{title:"Modern imaging of oligodendroglioma",source:"Villanueva-Meyer, J. E., et al. (2017). Neuro-Oncology",url:"https://doi.org/10.1093/neuonc/now150"},{title:"Advanced MRI Techniques for Glioma",source:"Lasocki, A., et al. (2020). AJNR Am J Neuroradiol",url:"https://doi.org/10.3174/ajnr.A6680"}].map((e,s)=>(0,a.jsxs)("li",{className:"break-inside-avoid",children:[(0,a.jsx)("span",{className:"font-semibold",children:e.title})," - ",e.source,".",(0,a.jsx)("a",{href:e.url,target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline ml-1",children:"[Access Link]"})]},s))})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsxs)("p",{children:["This infographic summarizes key findings on ","IDH-Mutated, 1p/19q Codeleted Oligodendroglioma"," based on current literature."]}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on ","October 9, 2025",". Generated with Gemini."]})]})]})},pineal_tumors_infographic_component:()=>{let{t:e}=(0,P.B)();return(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:[(0,a.jsx)(so,{children:"Pineal Region Tumors"}),": Radiological Aspects"]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"Differentiation Strategies in Pediatric and Adult Populations"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sd,{path:"M3.75 6.75h16.5M3.75 12h16.5m-16.5 5.25h16.5"}),"1. Introduction & Classification"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsxs)("p",{className:"text-base text-muted-foreground",children:["Pineal region tumors are rare (","<","1% of primary CNS tumors), arising near critical structures like the midbrain tectum and third ventricle, often causing hydrocephalus. The pineal region lacks a typical blood-brain barrier. Tumors are classified by origin (WHO 2021):"]}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-sm text-muted-foreground space-y-1 pl-4 mt-2",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Pineal Parenchymal Tumors (PPTs):"})," Pineocytoma (PC, Gr I/II), PPT of Intermediate Differentiation (PPTID, Gr II/III), Pineoblastoma (PB, Gr IV), Papillary Tumor (PTPR, Gr II/III)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Germ Cell Tumors (GCTs):"})," Most common in some regions (up to 60%). Germinoma (most frequent GCT), Nongerminomatous GCTs (NGGCTs: Choriocarcinoma, Embryonal Ca, Yolk Sac, Teratoma)."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Gliomas & Others:"})," Astrocytoma, Ependymoma, Meningioma, Metastases."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Cystic/Non-Neoplastic:"})," Pineal Cysts (common incidental finding)."]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sd,{path:"M12 21a9.004 9.004 0 008.716-6.747M12 21a9.004 9.004 0 01-8.716-6.747M12 21c.497 0 .98-.032 1.453-.091M12 21a8.958 8.958 0 01-1.453-.091m6.264-6.656a8.973 8.973 0 01-1.453.091M3.284 14.253a8.973 8.973 0 001.453.091M12 3a9.004 9.004 0 00-8.716 6.747M12 3a9.004 9.004 0 018.716 6.747M12 3c-.497 0-.98.032-1.453-.091M12 3a8.958 8.958 0 00-1.453-.091m6.264 6.656a8.973 8.973 0 001.453-.091M3.284 9.747a8.973 8.973 0 011.453-.091"}),"2. Epidemiology & Age Dichotomy"]})}),(0,a.jsxs)(p.Wu,{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("p",{className:"text-sm text-muted-foreground mb-2",children:"Patient age is crucial for differential diagnosis."}),(0,a.jsx)("h3",{className:"font-semibold text-destructive",children:"Pediatric Predominance:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-sm text-muted-foreground space-y-1 mb-3",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Pineoblastoma (PB):"})," WHO Gr IV, highly aggressive, peak < 20 yrs. ~45% of PPTs. High CSF spread risk."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Germinoma (GCT):"})," Frequent in children/young adults. Malignant but highly radiosensitive/chemosensitive. Marked male predominance (up to 11.8:1)."]})]}),(0,a.jsx)("h3",{className:"font-semibold",style:{color:"hsl(var(--chart-1))"},children:"Adult Predominance:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-sm text-muted-foreground space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Pineocytoma (PC):"})," WHO Gr I/II, most common PPT in adults (20-60 yrs). More common in females."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"PPTID:"})," WHO Gr II/III, peak 20-70 yrs."]})]})]}),(0,a.jsxs)(p.Zp,{className:"border-none shadow-none",children:[(0,a.jsx)(p.aR,{className:"p-2",children:(0,a.jsx)(p.ZB,{className:"text-base",children:"Typical Age Group by Tumor Type"})}),(0,a.jsx)(p.Wu,{className:"p-0",children:(0,a.jsx)("div",{className:"space-y-2",children:sx.map(e=>{var s;return(0,a.jsxs)("div",{className:"flex items-center text-xs",children:[(0,a.jsx)("div",{className:"w-4 h-4 rounded-sm mr-2",style:{backgroundColor:null===(s=su[e.key])||void 0===s?void 0:s.color}}),(0,a.jsxs)("span",{className:"font-medium w-28 mr-2",children:[e.name,":"]}),(0,a.jsx)("span",{children:e.ageGroup})]},e.name)})})})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sd,{path:"M2.25 15.75l5.159-5.159a2.25 2.25 0 013.182 0l5.159 5.159m-1.5-1.5l1.409-1.409a2.25 2.25 0 013.182 0l2.909 2.909m-18 3.75h16.5a1.5 1.5 0 001.5-1.5V6a1.5 1.5 0 00-1.5-1.5H3.75A1.5 1.5 0 002.25 6v12a1.5 1.5 0 001.5 1.5zm10.5-11.25h.008v.008h-.008V8.25zm.375 0a.375.375 0 11-.75 0 .375.375 0 01.75 0z"}),"3. Conventional Imaging & Calcification Pattern"]}),(0,a.jsx)(p.BT,{children:"MRI with contrast is standard. CT assesses calcifications and hydrocephalus."})]}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsxs)("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-4 text-sm mb-4",children:[(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-primary",children:"Exploded Calcification (Suggests PPT)"}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground",children:"PPTs (PC, PB) grow *from* pineocytes, displacing normal calcifications peripherally."})]}),(0,a.jsxs)("div",{children:[(0,a.jsx)("h3",{className:"font-semibold text-secondary",children:"Engulfed Calcification (Suggests GCT)"}),(0,a.jsx)("p",{className:"text-xs text-muted-foreground",children:"GCTs grow *around* the pineal gland, incorporating calcifications centrally."})]})]}),(0,a.jsx)("div",{className:"overflow-x-auto",children:(0,a.jsxs)(se.XI,{className:"text-xs",children:[(0,a.jsx)(se.A0,{children:(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nd,{children:"Tumor Type"}),(0,a.jsx)(se.nd,{children:"CT Density"}),(0,a.jsx)(se.nd,{children:"T1 Signal"}),(0,a.jsx)(se.nd,{children:"T2 Signal"}),(0,a.jsx)(se.nd,{children:"Enhancement"})]})}),(0,a.jsxs)(se.BF,{children:[(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Pineoblastoma (Gr IV)"}),(0,a.jsx)(se.nA,{children:"Hyperdense, Exploded Calc."}),(0,a.jsx)(se.nA,{children:"Iso/Hypointense"}),(0,a.jsx)(se.nA,{children:"Isointense"}),(0,a.jsx)(se.nA,{children:"Heterogeneous, Irregular"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Germinoma (GCT)"}),(0,a.jsx)(se.nA,{children:"Hyperdense, Engulfed Calc."}),(0,a.jsx)(se.nA,{children:"Isointense to GM"}),(0,a.jsx)(se.nA,{children:"Isointense to GM"}),(0,a.jsx)(se.nA,{children:"Strong, Homogeneous"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Pineocytoma (Gr I/II)"}),(0,a.jsx)(se.nA,{children:"Iso/Hypodense, Exploded Calc."}),(0,a.jsx)(se.nA,{children:"Low/Intermediate"}),(0,a.jsx)(se.nA,{children:"Intermediate/High"}),(0,a.jsx)(se.nA,{children:"Prominent, Nodular/Peripheral (if cystic)"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Teratoma (GCT)"}),(0,a.jsx)(se.nA,{children:"Mixed (Fat/Calc.)"}),(0,a.jsx)(se.nA,{children:"Mixed (High Fat)"}),(0,a.jsx)(se.nA,{children:"Mixed (Low Calc.)"}),(0,a.jsx)(se.nA,{children:"Solid Components Enhance"})]})]})]})})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsxs)(p.aR,{children:[(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sd,{path:"M10.5 6h9.75M10.5 6a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 10-3 0M3.75 6H7.5m3 12h9.75m-9.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-3.75 0H7.5m9-6h3.75m-3.75 0a1.5 1.5 0 01-3 0m3 0a1.5 1.5 0 00-3 0m-9.75 0h9.75"}),"4. Advanced MRI: DWI/ADC for Differentiation"]}),(0,a.jsx)(p.BT,{children:"DWI/ADC reflects cellular density and is crucial for distinguishing high-grade (highly cellular) tumors from low-grade/cystic lesions."})]}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("div",{className:"overflow-x-auto",children:(0,a.jsxs)(se.XI,{className:"text-xs",children:[(0,a.jsx)(se.A0,{children:(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nd,{children:"Tumor Type"}),(0,a.jsx)(se.nd,{children:"DWI Signal"}),(0,a.jsx)(se.nd,{children:"ADC Value"}),(0,a.jsx)(se.nd,{children:"Clinical Significance"})]})}),(0,a.jsxs)(se.BF,{children:[(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Pineoblastoma (Gr IV)"}),(0,a.jsx)(se.nA,{children:"High (Restricted)"}),(0,a.jsxs)(se.nA,{children:[(0,a.jsx)("strong",{className:"text-destructive",children:"Very Low"})," (e.g., ~343 x 10⁻⁶)"]}),(0,a.jsx)(se.nA,{children:"Indicates extreme cellularity (PNET)."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Germinoma (GCT)"}),(0,a.jsx)(se.nA,{children:"High (Restricted)"}),(0,a.jsxs)(se.nA,{children:[(0,a.jsx)("strong",{className:"text-orange-500",children:"Low, but > PB"})," (Thresholds proposed)"]}),(0,a.jsx)(se.nA,{children:"Highly cellular; ADC ratio ≤1.15 suggestive."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Pineocytoma (Gr I/II)"}),(0,a.jsx)(se.nA,{children:"Variable/Low"}),(0,a.jsxs)(se.nA,{children:[(0,a.jsx)("strong",{style:{color:"hsl(var(--chart-1))"},children:"Higher"})," (Less restricted)"]}),(0,a.jsx)(se.nA,{children:"Lower cellularity."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Pineal Cyst"}),(0,a.jsx)(se.nA,{children:"Low (No restriction)"}),(0,a.jsx)(se.nA,{children:(0,a.jsx)("strong",{className:"text-blue-500",children:"High (CSF-like)"})}),(0,a.jsx)(se.nA,{children:"Definitively excludes cellular tumor."})]})]})]})}),(0,a.jsxs)("p",{className:"text-xs text-muted-foreground mt-2",children:[(0,a.jsx)("strong",{className:"text-purple-500",children:"SWI:"})," Superior for calcification/hemorrhage (intense blooming in PB/Teratoma, minimal in Germinoma). ",(0,a.jsx)("strong",{className:"text-teal-500",children:"MRS:"})," Germinomas often show high lipids."]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sd,{path:"M9 12.75l3 3m0 0l3-3m-3 3v-7.5M21 12a9 9 0 11-18 0 9 9 0 0118 0zm-9-3.75h.008v.008H12V8.25z"}),"5. Differentiating Pineal Cysts"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("p",{className:"text-sm text-muted-foreground mb-2",children:"Pineal Cysts (PCs) are common incidental findings (1.5-23% prevalence). Must differentiate from neoplasms."}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-sm text-muted-foreground space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Typical MRI:"})," CSF-like signal (Low T1, High T2), often incomplete FLAIR suppression."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Enhancement Pitfall:"})," Thin peripheral rim enhancement (<2mm) is common and non-specific due to lack of BBB. Delayed scans may show diffuse filling."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Definitive Feature:"})," PCs show ",(0,a.jsx)("strong",{style:{color:"hsl(var(--chart-1))"},children:"NO restricted diffusion (High ADC)"}),", reliably distinguishing them from cellular tumors, even if enhancement is atypical."]})]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sd,{path:"M2.25 18L9 11.25l4.306 4.307a11.95 11.95 0 015.814-5.519l2.74-1.22m0 0l-1.37-1.37m1.37 1.37l-1.586 1.585"}),"6. Prognosis & Key Pointers"]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{className:"p-2",children:[(0,a.jsx)(p.ZB,{className:"text-base",children:"5-Year Survival by WHO Grade"}),(0,a.jsx)(p.BT,{className:"text-xs",children:"Illustrates the significant prognostic impact of grade."})]}),(0,a.jsx)(p.Wu,{className:"p-0",children:(0,a.jsx)(N,{config:sm,className:"min-h-[150px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:sh,children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"grade",tickLine:!1,axisLine:!1,tick:{fontSize:10}}),(0,a.jsx)(S.h,{unit:"%",domain:[0,100]}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot"})}),(0,a.jsx)(T.yP,{dataKey:"survival",name:"5-Year Survival",radius:[4,4,0,0],barSize:40,children:sh.map(e=>(0,a.jsx)(u.f,{fill:"var(--color-".concat(e.key,")")},"cell-".concat(e.key)))})]})})})})]}),(0,a.jsx)("h3",{className:"font-semibold text-foreground mb-1 mt-4",children:"Key Pointers Summary:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside text-sm text-muted-foreground space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Age Matters:"})," Pediatric favors PB/Germinoma; Adult favors PC/PPTID/Cyst."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"DWI/ADC is Crucial:"})," Restricted diffusion = high cellularity (PB/Germinoma); No restriction = Cyst/PC. Lower ADC suggests PB > Germinoma."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Calcification Pattern:"})," Exploded = PPT; Engulfed = GCT. Best seen on CT/SWI."]})]})]})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)(p.ZB,{className:"flex items-center text-xl",children:[(0,a.jsx)(sd,{path:"M12 6.042A8.967 8.967 0 006 3.75c-1.052 0-2.062.18-3 .512v14.25A8.987 8.987 0 016 18c2.305 0 4.408.867 6 2.292m0-14.25a8.966 8.966 0 016-2.292c1.052 0 2.062.18 3 .512v14.25A8.987 8.987 0 0018 18a8.967 8.967 0 00-6 2.292m0-14.25v14.25"}),"Sources"]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("ul",{className:"space-y-3 text-xs text-muted-foreground columns-1 md:columns-2",children:[{title:"Pineal gland tumors: Experience from the SEER database",source:"Konovalov, A. N., et al. (2010). Surgical Neurology International",url:"https://doi.org/10.4103/2152-7806.74157"},{title:"Radiation therapy for pineal parenchymal tumor of intermediate differentiation: A case series and literature review",source:"Khan, R. B., et al. (2023). Clinical Case Reports",url:"https://doi.org/10.1002/ccr3.7021"},{title:"Pineoblastoma",source:"Radiopaedia.org",url:"https://radiopaedia.org/articles/pineoblastoma"},{title:"Diagnosis and Management of Pineal Germinoma: From Eye to Brain",source:"Zhang, S., et al. (2023). Journal of Clinical Medicine",url:"https://doi.org/10.3390/jcm12082826"},{title:"Pineal Gland Cancer",source:"Toro, A., et al. (2022). In StatPearls. StatPearls Publishing",url:"https://www.ncbi.nlm.nih.gov/books/NBK560567/"},{title:"Pineal Region Tumors: Diagnosis and Treatment",source:"National Cancer Institute",url:"https://www.cancer.gov/rare-brain-spine-tumor/tumors/pineal-region-tumors"},{title:"Pineal parenchymal tumors",source:"Fauchon, F., et al. (2000). Brain Pathology",url:"https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1750-3639.2000.tb00244.x"},{title:"Magnetic resonance imaging of pineal region tumours",source:"Smith, A. B., et al. (2013). Clinical Radiology",url:"https://doi.org/10.1016/j.crad.2013.04.010"},{title:"Distinguishing between Germinomas and Pineal Cell Tumors on MR Imaging",source:"Chang, A. H., et al. (2012). AJNR Am J Neuroradiol",url:"https://doi.org/10.3174/ajnr.A2803"},{title:"Pineal Gland Tumors: A Review",source:"Berhouma, M. (2022). Cancers",url:"https://doi.org/10.3390/cancers13071547"}].map((e,s)=>(0,a.jsxs)("li",{className:"break-inside-avoid",children:[(0,a.jsx)("span",{className:"font-semibold",children:e.title})," - ",e.source,".",(0,a.jsx)("a",{href:e.url,target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline ml-1",children:"[Access Link]"})]},s))})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsxs)("p",{children:["This infographic summarizes key radiological aspects of ","Pineal Region Tumors"," based on current literature."]}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on ","October 9, 2025",". Generated with Gemini."]})]})]})},pcnsl_infographic_component:()=>{let{t:e}=(0,P.B)(),s=new Date().toLocaleDateString("en-US",{year:"numeric",month:"long",day:"numeric"});return(0,a.jsxs)("div",{className:"space-y-6",children:[(0,a.jsxs)("header",{className:"text-center mb-10",children:[(0,a.jsxs)("h1",{className:"text-3xl sm:text-4xl lg:text-5xl font-extrabold text-foreground tracking-tight",children:["Primary CNS ",(0,a.jsx)(sb,{children:"Lymphoma (PCNSL)"})]}),(0,a.jsx)("p",{className:"mt-2 text-lg text-muted-foreground",children:"Epidemiology, Etiopathogenesis, and Advanced Diagnostic Neuroimaging"})]}),(0,a.jsxs)("main",{className:"grid grid-cols-1 md:grid-cols-2 gap-6",children:[(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)("div",{className:"flex items-center",children:[(0,a.jsx)(sN,{icon:sp.A}),(0,a.jsx)(p.ZB,{children:"1. Introduction & Epidemiological Shifts"})]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"text-sm space-y-2 text-muted-foreground",children:[(0,a.jsx)("p",{children:"PCNSL is an aggressive extranodal NHL confined to the neuroaxis (brain, spine, eyes, leptomeninges), primarily DLBCL (>90%). It accounts for 3-4% of primary CNS tumors."}),(0,a.jsxs)("p",{children:["Incidence is low (~0.43-0.5/100k/year) but has shifted: ",(0,a.jsx)("strong",{className:"text-destructive",children:"declining in HIV+ patients"})," due to HAART (from 64% to 13% of cases) but ",(0,a.jsx)("strong",{className:"text-primary",children:"rising in the elderly immunocompetent"})," (65+ years)."]}),(0,a.jsx)("p",{children:"Median age: 67 (immunocompetent), 37 (HIV+), 52 (transplant). Male predominance in immunosuppressed groups."}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Key Risk Factor:"})," Immunodeficiency (HIV/AIDS, transplant immunosuppression). EBV is crucial in these settings."]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{className:"p-2",children:[(0,a.jsx)(p.ZB,{className:"text-base",children:"PCNSL Incidence Rates"}),(0,a.jsx)(p.BT,{className:"text-xs",children:"Rate per 100,000 person-years by group."})]}),(0,a.jsx)(p.Wu,{className:"p-0",children:(0,a.jsx)(N,{config:sA,className:"min-h-[200px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:200,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:sk,margin:{top:10,right:10,left:10,bottom:0},children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"group",tickLine:!1,axisLine:!1,tick:{fill:"hsl(var(--muted-foreground))",fontSize:9},angle:-30,textAnchor:"end",height:50,interval:0}),(0,a.jsx)(S.h,{tick:{fill:"hsl(var(--muted-foreground))",fontSize:10}}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot",hideLabel:!0})}),(0,a.jsx)(T.yP,{dataKey:"rate",name:"Incidence Rate",radius:[4,4,0,0],barSize:40,children:sk.map(e=>(0,a.jsx)(u.f,{fill:sA[e.key].color},"cell-".concat(e.key)))})]})})})})]})]})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)("div",{className:"flex items-center",children:[(0,a.jsx)(sN,{icon:sj.A}),(0,a.jsx)(p.ZB,{children:"2. Conventional Neuroimaging Features"})]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"text-sm space-y-2 text-muted-foreground",children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground mb-1",children:"Morphology & Location:"}),(0,a.jsxs)("ul",{className:"list-disc list-inside space-y-1",children:[(0,a.jsx)("li",{children:"Focal or multifocal masses. Solitary in immunocompetent, often multiple in immunocompromised."}),(0,a.jsx)("li",{children:"Predilection for periventricular WM, corpus callosum (24%), basal ganglia (27%), cerebral hemispheres (66%). Subependymal spread common."}),(0,a.jsx)("li",{children:"Signal: Typically T1 hypointense, T2 iso/hypointense relative to gray matter (due to high cellularity)."}),(0,a.jsx)("li",{children:"Hemorrhage: Foci visible on SWI in ~50%."})]})]}),(0,a.jsxs)("div",{className:"text-sm space-y-2 text-muted-foreground",children:[(0,a.jsx)("h3",{className:"font-semibold text-foreground mb-1",children:"Contrast Enhancement (Immune Status Dependent):"}),(0,a.jsxs)("ul",{className:"list-disc list-inside space-y-1",children:[(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Immunocompetent (Classic):"})," ",(0,a.jsx)("strong",{className:"text-primary",children:"Intense, homogeneous"})," enhancement is characteristic (>90%). Minimal necrosis."]}),(0,a.jsxs)("li",{children:[(0,a.jsx)("strong",{children:"Immunocompromised (Atypical):"})," Peripheral ",(0,a.jsx)("strong",{className:"text-destructive",children:"ring enhancement"})," or heterogeneous patterns common (10-15% overall). Central necrosis frequent, mimics toxoplasmosis."]})]})]})]})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)("div",{className:"flex items-center",children:[(0,a.jsx)(sN,{icon:sg.A}),(0,a.jsx)(p.ZB,{children:"3. Advanced Diagnostic Neuroimaging: Quantitative Biomarkers"})]})}),(0,a.jsxs)(p.Wu,{children:[(0,a.jsx)("div",{className:"overflow-x-auto",children:(0,a.jsxs)(se.XI,{className:"text-xs",children:[(0,a.jsx)(se.A0,{children:(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nd,{children:"Technique"}),(0,a.jsx)(se.nd,{children:"Metric"}),(0,a.jsx)(se.nd,{children:"Typical Finding in PCNSL"}),(0,a.jsx)(se.nd,{children:"Significance"})]})}),(0,a.jsxs)(se.BF,{children:[(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"DWI/ADC"}),(0,a.jsx)(se.nA,{children:"ADC Value"}),(0,a.jsxs)(se.nA,{children:[(0,a.jsx)("strong",{className:"text-destructive",children:"Significantly Low"})," (Restricted Diffusion, ~400-600 x 10⁻⁶)"]}),(0,a.jsx)(se.nA,{children:"Key differentiator vs. GBM & Toxo (higher ADC). Reflects extreme cellularity."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"PWI (Perfusion)"}),(0,a.jsx)(se.nA,{children:"rCBV (tumor core)"}),(0,a.jsx)(se.nA,{children:(0,a.jsx)("strong",{className:"text-primary",children:"Low or Modest Increase"})}),(0,a.jsx)(se.nA,{children:"Contrasts GBM (high rCBV). PCNSL uses host vessels, lacks intense neo-angiogenesis."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"PWI (Perfusion)"}),(0,a.jsx)(se.nA,{children:"rCBV (peritumoral)"}),(0,a.jsx)(se.nA,{children:"Low (similar to normal WM)"}),(0,a.jsx)(se.nA,{children:"Indicates pure vasogenic edema, unlike GBM's infiltrative (high rCBV) edema."})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"MRS"}),(0,a.jsx)(se.nA,{children:"Cho/NAA, Cho/Cr, Lipids/Lac"}),(0,a.jsx)(se.nA,{children:"↑↑Cho/NAA (>1.73), ↑Cho/Cr (>2.39), ↑↑Lipids/Lactate"}),(0,a.jsx)(se.nA,{children:"Reflects high proliferation & necrosis. Higher Lip/Lac correlates with worse survival."})]})]})]})}),(0,a.jsxs)("p",{className:"text-xs text-muted-foreground mt-2",children:["The combination of ",(0,a.jsx)("strong",{className:"text-destructive",children:"Low ADC"})," and ",(0,a.jsx)("strong",{className:"text-primary",children:"Low rCBV"})," is a powerful radiological signature for PCNSL."]})]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)("div",{className:"flex items-center",children:[(0,a.jsx)(sN,{icon:sf.A}),(0,a.jsx)(p.ZB,{children:"4. DDx: PCNSL vs. Glioblastoma (GBM)"})]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("div",{className:"overflow-x-auto",children:(0,a.jsxs)(se.XI,{className:"text-xs",children:[(0,a.jsx)(se.A0,{children:(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nd,{children:"Feature"}),(0,a.jsx)(se.nd,{children:"PCNSL"}),(0,a.jsx)(se.nd,{children:"GBM"})]})}),(0,a.jsxs)(se.BF,{children:[(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Enhancement"}),(0,a.jsx)(se.nA,{children:(0,a.jsx)("strong",{className:"text-primary",children:"Intense, Solid, Homogeneous"})}),(0,a.jsx)(se.nA,{children:"Irregular, Thick Ring"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Necrosis"}),(0,a.jsx)(se.nA,{children:"Minimal/Absent (Classic)"}),(0,a.jsx)(se.nA,{children:"Extensive Central Necrosis"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Tumor ADC"}),(0,a.jsx)(se.nA,{children:(0,a.jsx)("strong",{className:"text-destructive",children:"Low (Restricted)"})}),(0,a.jsx)(se.nA,{children:"Higher (Facilitated)"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Tumor rCBV"}),(0,a.jsx)(se.nA,{children:(0,a.jsx)("strong",{className:"text-primary",children:"Low/Modest"})}),(0,a.jsxs)(se.nA,{children:[(0,a.jsx)("strong",{className:"text-destructive",children:"High"})," (Neo-angiogenesis)"]})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Peritumoral rCBV"}),(0,a.jsx)(se.nA,{children:"Low (Vasogenic Edema)"}),(0,a.jsxs)(se.nA,{children:[(0,a.jsx)("strong",{className:"text-destructive",children:"High"})," (Tumor Infiltration)"]})]})]})]})})})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)("div",{className:"flex items-center",children:[(0,a.jsx)(sN,{icon:sf.A}),(0,a.jsx)(p.ZB,{children:"5. DDx: PCNSL vs. Toxoplasmosis"})]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsx)("div",{className:"overflow-x-auto",children:(0,a.jsxs)(se.XI,{className:"text-xs",children:[(0,a.jsx)(se.A0,{children:(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nd,{children:"Feature"}),(0,a.jsx)(se.nd,{children:"PCNSL (Immunocompromised)"}),(0,a.jsx)(se.nd,{children:"Cerebral Toxoplasmosis"})]})}),(0,a.jsxs)(se.BF,{children:[(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Multiplicity"}),(0,a.jsx)(se.nA,{children:"Solitary or Multiple (~50/50)"}),(0,a.jsx)(se.nA,{children:"Multiple (most common)"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Location"}),(0,a.jsx)(se.nA,{children:"Periventricular WM, CC, BG"}),(0,a.jsx)(se.nA,{children:"BG, Thalamus, Corticomedullary Junction"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"Enhancement"}),(0,a.jsx)(se.nA,{children:"Ring Enhancement Common"}),(0,a.jsx)(se.nA,{children:'Ring Enhancement ("Target Sign")'})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"ADC"}),(0,a.jsx)(se.nA,{children:(0,a.jsx)("strong",{className:"text-destructive",children:"Low (Restricted)"})}),(0,a.jsx)(se.nA,{children:"Higher (Facilitated - Necrosis)"})]}),(0,a.jsxs)(se.Hj,{children:[(0,a.jsx)(se.nA,{className:"font-medium",children:"PET/SPECT"}),(0,a.jsxs)(se.nA,{children:[(0,a.jsx)("strong",{className:"text-primary",children:"High Metabolic Uptake"})," (FDG/Thallium Avid)"]}),(0,a.jsx)(se.nA,{children:"Low Metabolic Uptake (Non-Avid)"})]})]})]})})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)("div",{className:"flex items-center",children:[(0,a.jsx)(sN,{icon:sy.A}),(0,a.jsx)(p.ZB,{children:"6. Prognosis & Therapeutic Implications"})]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("div",{className:"grid grid-cols-1 lg:grid-cols-2 gap-6",children:[(0,a.jsxs)("div",{className:"text-sm space-y-2 text-muted-foreground",children:[(0,a.jsx)("p",{children:"Prognosis remains challenging but has improved. Accurate non-invasive diagnosis guides therapy."}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Treatment:"})," Primarily high-dose methotrexate (HD-MTX) based chemotherapy. Surgery is generally contraindicated and harmful."]}),(0,a.jsxs)("p",{children:[(0,a.jsx)("strong",{children:"Diagnostic Impact:"})," Differentiating PCNSL from GBM avoids unnecessary surgery. Distinguishing from Toxo in HIV+ patients guides initial anti-infective trial vs. biopsy/chemo."]})]}),(0,a.jsxs)(p.Zp,{children:[(0,a.jsxs)(p.aR,{className:"p-2",children:[(0,a.jsx)(p.ZB,{className:"text-base",children:"PCNSL 5-Year Survival Rates"}),(0,a.jsx)(p.BT,{className:"text-xs",children:"Comparison by immune status (historical data)."})]}),(0,a.jsx)(p.Wu,{className:"p-0",children:(0,a.jsx)(N,{config:sw,className:"min-h-[150px] w-full",children:(0,a.jsx)(h.u,{width:"100%",height:150,children:(0,a.jsxs)(I.E,{accessibilityLayer:!0,data:sC,margin:{top:10,right:10,left:10,bottom:0},children:[(0,a.jsx)(M.d,{vertical:!1}),(0,a.jsx)(R.W,{dataKey:"group",tickLine:!1,axisLine:!1,tick:{fill:"hsl(var(--muted-foreground))",fontSize:10}}),(0,a.jsx)(S.h,{unit:"%",tick:{fill:"hsl(var(--muted-foreground))",fontSize:10}}),(0,a.jsx)(j.m,{cursor:!1,content:(0,a.jsx)(C,{indicator:"dot",hideLabel:!0})}),(0,a.jsx)(T.yP,{dataKey:"survival",name:"5-Yr Survival",radius:[4,4,0,0],barSize:40,children:sC.map(e=>(0,a.jsx)(u.f,{fill:sw[e.key].color},"cell-".concat(e.key)))})]})})})})]})]})}),(0,a.jsx)(p.wL,{children:(0,a.jsx)("p",{className:"text-xs text-muted-foreground mt-4",children:"Untreated PCNSL is often fatal within 2-6 months. Prognosis is poor if immune reconstitution is not possible (e.g., certain malignancies)."})})]}),(0,a.jsxs)(p.Zp,{className:"md:col-span-2",children:[(0,a.jsx)(p.aR,{children:(0,a.jsxs)("div",{className:"flex items-center",children:[(0,a.jsx)(sN,{icon:sv.A}),(0,a.jsx)(p.ZB,{children:"Sources"})]})}),(0,a.jsx)(p.Wu,{children:(0,a.jsxs)("ul",{className:"space-y-3 text-xs text-muted-foreground columns-1 md:columns-2",children:[(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Villano, J. L., et al. (2011). Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. *British Journal of Cancer*, *105*(9), 1414–1818. ",(0,a.jsx)("a",{href:"https://doi.org/10.1038/bjc.2011.357",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Al Tawalbeh, S., & Tadi, P. (2023). Central Nervous System Lymphoma. In *StatPearls*. StatPearls Publishing. Retrieved from ",(0,a.jsx)("a",{href:"https://www.ncbi.nlm.nih.gov/books/NBK545145/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NCBI Bookshelf"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Lauria, F., et al. (2022). Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. *Journal of Neuro-Oncology*, *160*(1), 129-141. ",(0,a.jsx)("a",{href:"https://doi.org/10.1007/s11060-022-04149-x",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Kwon, M., et al. (2010). MRI Findings of Primary CNS Lymphoma in 26 Immunocompetent Patients. *Korean Journal of Radiology*, *11*(3), 275-283. ",(0,a.jsx)("a",{href:"https://doi.org/10.3348/kjr.2010.11.3.275",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Shiels, M. S., et al. (2016). Trends in Primary Central Nervous System Lymphoma Incidence and Survival in the U.S. *British Journal of Haematology*, *174*(3), 417-424. ",(0,a.jsx)("a",{href:"https://doi.org/10.1111/bjh.14073",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Radiopaedia.org. (n.d.). *Lymphomas of the central nervous system*. Retrieved ",s,", from ",(0,a.jsx)("a",{href:"https://radiopaedia.org/articles/lymphomas-of-the-central-nervous-system",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"Radiopaedia.org"})]}),(0,a.jsx)("li",{className:"break-inside-avoid",children:"B\xfchring, U., et al. (2001). MRI features of primary central nervous system lymphomas at presentation. *Neurology*, *57*(3), 393-396. (Implied source for ResearchGate 7815994)"}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Sailer, M., et al. (2021). MRI imaging features of HIV-related central nervous system diseases: diagnosis by pattern recognition in daily practice. *Clinical Neuroradiology*, *31*(4), 1145–1162. ",(0,a.jsx)("a",{href:"https://doi.org/10.1007/s00062-021-01053-9",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Wang, S., et al. (2022). Differentiation Between Primary Central Nervous System Lymphoma and Atypical Glioblastoma Based on MRI. *Frontiers in Oncology*, *12*, 811197. ",(0,a.jsx)("a",{href:"https://doi.org/10.3389/fonc.2022.811197",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI"})]}),(0,a.jsxs)("li",{className:"break-inside-avoid",children:["Hu, L. S., et al. (2022). Differentiation of glioblastoma and primary central nervous system lymphomas using multiparametric diffusion and perfusion MRI. *Frontiers in Oncology*, *12*, 995804. ",(0,a.jsx)("a",{href:"https://doi.org/10.3389/fonc.2022.995804",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"DOI"})]})]})})]})]}),(0,a.jsxs)("footer",{className:"text-center mt-10 text-xs text-muted-foreground",children:[(0,a.jsx)("p",{children:"This infographic summarizes key radiological characteristics of Primary CNS Lymphoma based on current literature."}),(0,a.jsx)("p",{children:"For educational purposes only. Not a substitute for professional medical advice."}),(0,a.jsxs)("p",{className:"mt-2",children:["Created by ",(0,a.jsx)("a",{href:"https://www.neuroradx.de/",target:"_blank",rel:"noopener noreferrer",className:"text-primary hover:underline",children:"NeuroRadX"})," on ",s,". Generated with Gemini."]})]})]})}};function sM(e){let{infographicId:s}=e,r=(0,t.useRouter)(),{t:h}=(0,P.B)(),[m,x]=(0,i.useState)(!0),[u,p]=(0,i.useState)(null);return((0,i.useEffect)(()=>{let e=sI[s];e?p(()=>e):p(null),x(!1)},[s]),m)?(0,a.jsx)("div",{className:"flex items-center justify-center min-h-[calc(100vh-200px)]",children:(0,a.jsx)(l.A,{className:"h-12 w-12 animate-spin text-primary"})}):(0,a.jsxs)("div",{className:"container mx-auto py-8",children:[(0,a.jsxs)(n.$,{onClick:()=>r.back(),variant:"outline",className:"mb-6",children:[(0,a.jsx)(c.A,{className:"mr-2 h-4 w-4"})," ",h("infographics.backToList")]}),u?(0,a.jsx)(u,{}):(0,a.jsxs)(d.Fc,{variant:"destructive",children:[(0,a.jsx)(o.A,{className:"h-4 w-4"}),(0,a.jsx)(d.XL,{children:h("infographics.notFoundTitle")}),(0,a.jsx)(d.TN,{children:h("infographics.notFoundDescription")})]})]})}},38002:(e,s,r)=>{"use strict";r.d(s,{Fc:()=>c,TN:()=>d,XL:()=>o});var a=r(95155),i=r(12115),t=r(40652),n=r(21567);let l=(0,t.F)("relative w-full rounded-lg border p-4 [&>svg~*]:pl-7 [&>svg+div]:translate-y-[-3px] [&>svg]:absolute [&>svg]:left-4 [&>svg]:top-4 [&>svg]:text-foreground",{variants:{variant:{default:"bg-background text-foreground",destructive:"bg-destructive/10 border-destructive/50 text-destructive dark:bg-destructive/20 dark:border-destructive/60 dark:text-destructive-foreground [&>svg]:text-destructive dark:[&>svg]:text-destructive-foreground"}},defaultVariants:{variant:"default"}}),c=i.forwardRef((e,s)=>{let{className:r,variant:i,...t}=e;return(0,a.jsx)("div",{ref:s,role:"alert",className:(0,n.cn)(l({variant:i}),r),...t})});c.displayName="Alert";let o=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("h5",{ref:s,className:(0,n.cn)("mb-1 font-medium leading-none tracking-tight",r),...i})});o.displayName="AlertTitle";let d=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("div",{ref:s,className:(0,n.cn)("text-sm [&_p]:leading-relaxed",r),...i})});d.displayName="AlertDescription"},73312:(e,s,r)=>{"use strict";r.d(s,{$:()=>o,r:()=>c});var a=r(95155),i=r(12115),t=r(12317),n=r(40652),l=r(21567);let c=(0,n.F)("inline-flex items-center justify-center whitespace-nowrap rounded-md text-sm font-medium ring-offset-background transition-colors focus-visible:outline-none focus-visible:ring-2 focus-visible:ring-ring focus-visible:ring-offset-2 disabled:pointer-events-none disabled:opacity-50",{variants:{variant:{default:"bg-primary text-primary-foreground hover:bg-primary/90",destructive:"bg-destructive text-destructive-foreground hover:bg-destructive/90",outline:"border border-input bg-background hover:bg-accent hover:text-accent-foreground",secondary:"bg-secondary text-secondary-foreground hover:bg-secondary/80",ghost:"hover:bg-accent hover:text-accent-foreground",link:"text-primary underline-offset-4 hover:underline"},size:{default:"h-10 px-4 py-2",sm:"h-9 rounded-md px-3",lg:"h-11 rounded-md px-8",icon:"h-10 w-10"}},defaultVariants:{variant:"default",size:"default"}}),o=i.forwardRef((e,s)=>{let{className:r,variant:i,size:n,asChild:o=!1,...d}=e,h=o?t.DX:"button";return(0,a.jsx)(h,{className:(0,l.cn)(c({variant:i,size:n,className:r})),ref:s,...d})});o.displayName="Button"},22130:(e,s,r)=>{"use strict";r.d(s,{BT:()=>o,Wu:()=>d,ZB:()=>c,Zp:()=>n,aR:()=>l,wL:()=>h});var a=r(95155),i=r(12115),t=r(21567);let n=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("div",{ref:s,className:(0,t.cn)("rounded-lg border bg-card text-card-foreground shadow-sm",r),...i})});n.displayName="Card";let l=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("div",{ref:s,className:(0,t.cn)("flex flex-col space-y-1.5 p-6",r),...i})});l.displayName="CardHeader";let c=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("h3",{ref:s,className:(0,t.cn)("text-2xl font-semibold leading-none tracking-tight",r),...i})});c.displayName="CardTitle";let o=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("p",{ref:s,className:(0,t.cn)("text-sm text-muted-foreground",r),...i})});o.displayName="CardDescription";let d=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("div",{ref:s,className:(0,t.cn)("p-6 pt-0",r),...i})});d.displayName="CardContent";let h=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("div",{ref:s,className:(0,t.cn)("flex items-center p-6 pt-0",r),...i})});h.displayName="CardFooter"},72508:(e,s,r)=>{"use strict";r.d(s,{A0:()=>l,BF:()=>c,Hj:()=>o,XI:()=>n,nA:()=>h,nd:()=>d});var a=r(95155),i=r(12115),t=r(21567);let n=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("div",{className:"relative w-full overflow-auto",children:(0,a.jsx)("table",{ref:s,className:(0,t.cn)("w-full caption-bottom text-sm",r),...i})})});n.displayName="Table";let l=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("thead",{ref:s,className:(0,t.cn)("[&_tr]:border-b",r),...i})});l.displayName="TableHeader";let c=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("tbody",{ref:s,className:(0,t.cn)("[&_tr:last-child]:border-0",r),...i})});c.displayName="TableBody",i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("tfoot",{ref:s,className:(0,t.cn)("border-t bg-muted/50 font-medium [&>tr]:last:border-b-0",r),...i})}).displayName="TableFooter";let o=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("tr",{ref:s,className:(0,t.cn)("border-b transition-colors hover:bg-muted/50 data-[state=selected]:bg-muted",r),...i})});o.displayName="TableRow";let d=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("th",{ref:s,className:(0,t.cn)("h-12 px-4 text-left align-middle font-medium text-muted-foreground [&:has([role=checkbox])]:pr-0",r),...i})});d.displayName="TableHead";let h=i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("td",{ref:s,className:(0,t.cn)("p-4 align-middle [&:has([role=checkbox])]:pr-0",r),...i})});h.displayName="TableCell",i.forwardRef((e,s)=>{let{className:r,...i}=e;return(0,a.jsx)("caption",{ref:s,className:(0,t.cn)("mt-4 text-sm text-muted-foreground",r),...i})}).displayName="TableCaption"}}]);